Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders

1.

Aartsma-Rus, A., Straub, V., Hemmings, R., Haas, M., Schlosser-Weber, G., Stoyanova-Beninska, V., Mercuri, E., Muntoni, F., Sepodes, B., Vroom, E., & Balabanov, P. (2017). Development of exon skipping therapies for duchenne muscular dystrophy: A critical review and a perspective on the outstanding issues [Review]. Nucleic Acid Therapeutics, 27(5), 251–259. https://doi.org/10.1089/nat.2017.0682CrossRefPubMedPubMedCentral

2.

Ahn, A. H., & Kunkel, L. M. (1993). The structural and functional diversity of dystrophin. Nature Genetics, 3(4), 283–291. https://doi.org/10.1038/ng0493-283CrossRefPubMed

3.

Al-Zaidy, S. A., & Mendell, J. R. (2019). From clinical trials to clinical practice: Practical considerations for gene replacement therapy in SMA Type 1. Pediatric Neurology, 100, 3–11. https://doi.org/10.1016/j.pediatrneurol.2019.06.007CrossRefPubMed

4.

Alami, N. H., Smith, R. B., Carrasco, M. A., Williams, L. A., Winborn, C. S., Han, S. S. W., Kiskinis, E., Winborn, B., Freibaum, B. D., Kanagaraj, A., Clare, A. J., Badders, N. M., Bilican, B., Chaum, E., Chandran, S., Shaw, C. E., Eggan, K. C., Maniatis, T., & Taylor, J. P. (2014). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Neuron, 81(3), 536–543. https://doi.org/10.1016/j.neuron.2013.12.018CrossRefPubMedPubMedCentral

5.

Alrafiah, A., Karyka, E., Coldicott, I., Iremonger, K., Lewis, K. E., Ning, K., & Azzouz, M. (2018). Plastin 3 promotes motor neuron axonal growth and extends survival in a mouse model of spinal muscular atrophy. Molecular Therapy-Methods & Clinical Development, 9, 81–89. https://doi.org/10.1016/j.omtm.2018.01.007CrossRef

6.

Andersen, P. M., Forsgren, L., Binzer, M., Nilsson, P., Ala-Hurula, V., Keranen, M. L., Bergmark, L., Saarinen, A., Haltia, T., Tarvainen, I., Kinnunen, E., Udd, B., & Marklund, S. L. (1996). Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients [Research Support, Non-U.S. Gov’t]. Brain, 119(Pt 4), 1153–1172. https://doi.org/10.1093/brain/119.4.1153CrossRefPubMed

7.

Andersen, P. M., Nilsson, P., Ala Hurula, V., Keranen, M. L., Tarvainen, I., Haltia, T., Nilsson, L., Binzer, M., Forsgren, L., & Marklund, S. L. (1995). Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nature Genetics, 10, 61–66.PubMedCrossRef

8.

Andersen, P. M., Nilsson, P., Forsgren, L., & Marklund, S. L. (1998). CuZn-superoxide dismutase, extracellular superoxide dismutase, and glutathione peroxidase in blood from individuals homozygous for Asp90Ala CuZu-superoxide dismutase mutation [Research Support, Non-U.S. Gov’t]. Journal of Neurochemistry, 70(2), 715–720. https://doi.org/10.1046/j.1471-4159.1998.70020715.xCrossRefPubMed

9.

Andrews, J. A., Miller, T. M., Vijayakumar, V., Stoltz, R., James, J. K., Meng, L., Wolff, A. A., & Malik, F. I. (2018). CK-2127107 amplifies skeletal muscle response to nerve activation in humans [Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Muscle and Nerve, 57(5), 729–734. https://doi.org/10.1002/mus.26017CrossRefPubMed

10.

Aragon-Gawinska, K., Seferian, A. M., Daron, A., Gargaun, E., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., Rambaud, J., Taytard, J., Annoussamy, M., Scoto, M., Gidaro, T., & Servais, L. (2018). Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study [Clinical Trial Research Support, Non-U.S. Gov’t]. Neurology, 91(14), e1312–e1318. https://doi.org/10.1212/WNL.0000000000006281CrossRefPubMed

11.

Arakawa, Y., Sendtner, M., & Thoenen, H. (1990). Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: Comparison with other neurotrophic factors and cytokines. Journal of Neuroscience, 10, 3507–3515.PubMedCrossRef

12.

Arnold, A. S., Gueye, M., Guettier-Sigrist, S., Courdier-Fruh, I., Coupin, G., Poindron, P., & Gies, J. P. (2004). Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients [Research Support, Non-U.S. Gov’t]. Laboratory Investigation, 84(10), 1271–1278. https://doi.org/10.1038/labinvest.3700163CrossRefPubMed

13.

Arnold, C. (2019). Custom therapies pose huge financial burdens. Nature Medicine. https://doi.org/10.1038/d41591-019-00021-wCrossRefPubMed

14.

Arnold, C. (2019). Tailored treatment for ALS poised to move ahead. Nature Medicine. https://doi.org/10.1038/d41591-019-00013-wCrossRefPubMed

15.

Ash, P. E., Bieniek, K. F., Gendron, T. F., Caulfield, T., Lin, W. L., Dejesus-Hernandez, M., van Blitterswijk, M. M., Jansen-West, K., Paul, J. W., 3rd., Rademakers, R., Boylan, K. B., Dickson, D. W., & Petrucelli, L. (2013). Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Neuron, 77(4), 639–646. https://doi.org/10.1016/j.neuron.2013.02.004CrossRefPubMedPubMedCentral

16.

Aslesh, T., Maruyama, R., & Yokota, T. (2018). Skipping multiple exons to treat DMD-promises and challenges [review]. Biomedicines, 6(1), 1. https://doi.org/10.3390/biomedicines6010001CrossRefPubMedCentral

17.

Azzouz, M., Le, T., Ralph, G. S., Walmsley, L., Monani, U. R., Lee, D. C., Wilkes, F., Mitrophanous, K. A., Kingsman, S. M., Burghes, A. H., & Mazarakis, N. D. (2004). Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. The Journal of Clinical Investigation, 114(12), 1726–1731. https://doi.org/10.1172/JCI22922CrossRefPubMedPubMedCentral

18.

Baldwin, K. R., Godena, V. K., Hewitt, V. L., & Whitworth, A. J. (2016). Axonal transport defects are a common phenotype in Drosophila models of ALS. Human Molecular Genetics, 25(12), 2378–2392. https://doi.org/10.1093/hmg/ddw105CrossRefPubMedPubMedCentral

19.

Baranello, G., Darras, B. T., Day, J. W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Seabrook, T., Fontoura, P., Servais, L., & Group, F. W. (2021). Risdiplam in Type 1 Spinal Muscular Atrophy. New England Journal of Medicine, 384(10), 915–923. https://doi.org/10.1056/NEJMoa2009965CrossRefPubMed

20.

Battaglia, G., Princivalle, A., Forti, F., Lizier, C., & Zeviani, M. (1997). Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Human Molecular Genetics, 6(11), 1961–1971.PubMedCrossRef

21.

Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., Pulst, S. M., Taylor, J. P., Rigo, F., & Gitler, A. D. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature, 544(7650), 367–371. https://doi.org/10.1038/nature22038CrossRefPubMedPubMedCentral

22.

Berciano, M. T., Castillo-Iglesias, M. S., Val-Bernal, J. F., Lafarga, V., Rodriguez-Rey, J. C., Lafarga, M., & Tapia, O. (2020). Mislocalization of SMN from the I-band and M-band in human skeletal myofibers in spinal muscular atrophy associates with primary structural alterations of the sarcomere. Cell and Tissue Research, 381(3), 461–478. https://doi.org/10.1007/s00441-020-03236-3CrossRefPubMed

23.

Bertini, E., Gadisseux, J. L., Palmieri, G., Ricci, E., Di, C. M., Ferriere, G., & Lyon, G. (1989). Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: a variant of infantile spinal muscular atrophy. American Journal of Medical Genetics, 33(3), 328–335.PubMedCrossRef

24.

Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H., Lamont, L., Roy, A. J., Chamova, T., Guergueltcheva, V., Chan, S., Korngut, L., Campbell, C., Dai, Y., Wang, J., Barisic, N., Brabec, P., Lahdetie, J., … Lochmuller, H. (2015). The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations [Research Support, Non-U.S. Gov’t]. Human Mutatation, 36(4), 395–402. https://doi.org/10.1002/humu.22758CrossRef

25.

Bordet, T., Berna, P., Abitbol, J. L., & Pruss, R. M. (2010). Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals (Basel), 3(2), 345–368. https://doi.org/10.3390/ph3020345CrossRef

26.

Bosch-Marce, M., Wee, C. D., Martinez, T. L., Lipkes, C. E., Choe, D. W., Kong, L., Van Meerbeke, J. P., Musaro, A., & Sumner, C. J. (2011). Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Human Molecular Genetics, 20(9), 1844–1853.PubMedPubMedCentralCrossRef

27.

Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Human Gene Therapy, 21(6), 704–712. https://doi.org/10.1089/hum.2009.182CrossRefPubMed

28.

Bowerman, M., Becker, C. G., Yanez-Munoz, R. J., Ning, K., Wood, M. J. A., Gillingwater, T. H., Talbot, K., & Consortium, U. S. R. (2017). Therapeutic strategies for spinal muscular atrophy: SMN and beyond [Review Research Support, Non-U.S. Gov’t]. Disease Models & Mechanisms, 10(8), 943–954. https://doi.org/10.1242/dmm.030148CrossRef

29.

Braun, R., Wang, Z., Mack, D. L., & Childers, M. K. (2014). Gene therapy for inherited muscle diseases: Where genetics meets rehabilitation medicine [Review]. American Journal of Physical Medicine and Rehabilitation, 93(11 Suppl 3), S97-107. https://doi.org/10.1097/PHM.0000000000000138CrossRefPubMed

30.

Braun, S., Croizat, B., Lagrange, M. C., Warter, J. M., & Poindron, P. (1995). Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet, 345(8951), 694–695. https://doi.org/10.1016/s0140-6736(95)90869-2CrossRefPubMed

31.

Bricceno, K. V., Martinez, T., Leikina, E., Duguez, S., Partridge, T. A., Chernomordik, L. V., Fischbeck, K. H., Sumner, C. J., & Burnett, B. G. (2014). Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Human Molecular Genetics, 23(18), 4745–4757. https://doi.org/10.1093/hmg/ddu189CrossRefPubMedPubMedCentral

32.

Briese, M., Saal-Bauernschubert, L., Ji, C., Moradi, M., Ghanawi, H., Uhl, M., Appenzeller, S., Backofen, R., & Sendtner, M. (2018). hnRNP R and its main interactor, the noncoding RNA 7SK, coregulate the axonal transcriptome of motoneurons [Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences USA, 115(12), E2859–E2868. https://doi.org/10.1073/pnas.1721670115CrossRef

33.

Briese, M., Saal-Bauernschubert, L., Luningschror, P., Moradi, M., Dombert, B., Surrey, V., Appenzeller, S., Deng, C., Jablonka, S., & Sendtner, M. (2020). Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathologica Communications, 8(1), 116. https://doi.org/10.1186/s40478-020-00987-6CrossRefPubMedPubMedCentral

34.

Briese, M., Saal, L., Appenzeller, S., Moradi, M., Baluapuri, A., & Sendtner, M. (2016). Whole transcriptome profiling reveals the RNA content of motor axons. Nucleic Acids Research., 44(4), e33.PubMedCrossRef

35.

Broustal, O., Camuzat, A., Guillot-Noel, L., Guy, N., Millecamps, S., Deffond, D., Lacomblez, L., Golfier, V., Hannequin, D., Salachas, F., Camu, W., Didic, M., Dubois, B., Meininger, V., Le Ber, I., Brice, A., French, C., & genetic research network on, F. F.-M. (2010). FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. Journal of Alzheimer’s Disease, 22(3), 765–769.PubMed

36.

Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., Ohama, E., Reaume, A. G., Scott, R. W., & Cleveland, D. W. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1 [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Science, 281(5384), 1851–1854. https://doi.org/10.1126/science.281.5384.1851CrossRefPubMed

37.

Burghes, A. H. (1997). When is a deletion not a deletion? When it is converted. American Journal of Human Genetics, 61(1), 9–15.PubMedPubMedCentralCrossRef

38.

Burlet, P., Huber, C., Bertrandy, S., Ludosky, M. A., Zwaenepoel, I., Clermont, O., Roume, J., Delezoide, A. L., Cartaud, J., Munnich, A., & Lefebvre, S. (1998). The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Human Molecular Genetics, 7(12), 1927–1933.PubMedCrossRef

39.

Campagne, S., Boigner, S., Rudisser, S., Moursy, A., Gillioz, L., Knorlein, A., Hall, J., Ratni, H., Clery, A., & Allain, F. H. (2019). Structural basis of a small molecule targeting RNA for a specific splicing correction [Research Support, Non-U.S. Gov’t]. Nature Chemical Biology, 15(12), 1191–1198. https://doi.org/10.1038/s41589-019-0384-5CrossRefPubMed

40.

Campbell, L., Potter, A., Ignatius, J., Dubowitz, V., & Davies, K. (1997). Genomic variation and gene conversion in spinal muscular atrophy: Implications for disease process and clinical phenotype. American Journal of Human Genetics, 61(1), 40–50.PubMedPubMedCentralCrossRef

41.

Carter, J. C., Sheehan, D. W., Prochoroff, A., & Birnkrant, D. J. (2018). Muscular dystrophies [review]. Clinics in Chest Medicine, 39(2), 377–389. https://doi.org/10.1016/j.ccm.2018.01.004CrossRefPubMed

42.

Chia, R., Chio, A., & Traynor, B. J. (2018). Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications [Review]. Lancet Neurology, 17(1), 94–102. https://doi.org/10.1016/S1474-4422(17)30401-5CrossRefPubMed

43.

Chicoine, L. G., Rodino-Klapac, L. R., Shao, G., Xu, R., Bremer, W. G., Camboni, M., Golden, B., Montgomery, C. L., Shontz, K., Heller, K. N., Griffin, D. A., Lewis, S., Coley, B. D., Walker, C. M., Clark, K. R., Sahenk, Z., Mendell, J. R., & Martin, P. T. (2014). Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Molecular Therapy, 22(4), 713–724. https://doi.org/10.1038/mt.2013.246CrossRefPubMedPubMedCentral

44.

Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016). Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy [Clinical Trial, Phase I Multicenter Study Research Support, Non-U.S. Gov’t]. Neurology, 86(10), 890–897. https://doi.org/10.1212/WNL.0000000000002445CrossRefPubMedPubMedCentral

45.

Cho, S., & Dreyfuss, G. (2010). A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity [Research Support, Non-U.S. Gov’t]. Genes & Development, 24(5), 438–442. https://doi.org/10.1101/gad.1884910CrossRef

46.

Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73(20), 1662–1669. https://doi.org/10.1212/WNL.0b013e3181c29356CrossRefPubMedPubMedCentral

47.

Cifuentes-Diaz, C., Frugier, T., Tiziano, F. D., Lacene, E., Roblot, N., Joshi, V., Moreau, M. H., & Melki, J. (2001). Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. Journal of Cell Biology, 152(5), 1107–1114. https://doi.org/10.1083/jcb.152.5.1107CrossRefPubMedPubMedCentral

48.

Cleveland, D. W., Laing, N., Hurse, P. V., & Brown, R. H., Jr. (1995). Toxic mutants in Charcot’s sclerosis [Comment Letter]. Nature, 378(6555), 342–343. https://doi.org/10.1038/378342a0CrossRefPubMed

49.

Congdon, E. E., & Sigurdsson, E. M. (2018). Tau-targeting therapies for Alzheimer disease [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Nature Reviews Neurology, 14(7), 399–415. https://doi.org/10.1038/s41582-018-0013-zCrossRefPubMedPubMedCentral

50.

Coovert, D. D., Le, T. T., McAndrew, P. E., Strasswimmer, J., Crawford, T. O., Mendell, J. R., Coulson, S. E., Androphy, E. J., Prior, T. W., & Burghes, A. H. (1997). The survival motor neuron protein in spinal muscular atrophy. Human Molecular Genetics, 6(8), 1205–1214.PubMedCrossRef

51.

Cox, G. A., Mahaffey, C. L., & Frankel, W. N. (1998). Identification of the mouse neuromuscular degeneration gene and mapping of a second site suppressor allele. Neuron, 21(6), 1327–1337.PubMedCrossRef

52.

Crudele, J. M., & Chamberlain, J. S. (2019). AAV-based gene therapies for the muscular dystrophies. Human Molecular Genetics, 28(R1), R102–R107. https://doi.org/10.1093/hmg/ddz128CrossRefPubMedPubMedCentral

53.

d’Ydewalle, C., Ramos, D. M., Pyles, N. J., Ng, S. Y., Gorz, M., Pilato, C. M., Ling, K., Kong, L., Ward, A. J., Rubin, L. L., Rigo, F., Bennett, C. F., & Sumner, C. J. (2017). The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron, 93(1), 66–79.PubMedCrossRef

54.

Darras, B. T., Chiriboga, C. A., Iannaccone, S. T., Swoboda, K. J., Montes, J., Mignon, L., Xia, S., Bennett, C. F., Bishop, K. M., Shefner, J. M., Green, A. M., Sun, P., Bhan, I., Gheuens, S., Schneider, E., Farwell, W., De Vivo, D. C., & Groups, I.-C. I.-C. S. (2019). Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov’t]. Neurology, 92(21), e2492–e2506. https://doi.org/10.1212/WNL.0000000000007527CrossRefPubMedPubMedCentral

55.

Darras, B. T., Masson, R., Mazurkiewicz-Beldzinska, M., Rose, K., Xiong, H., Zanoteli, E., Baranello, G., Bruno, C., Vlodavets, D., Wang, Y., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R. S., Fontoura, P., Servais, L., & Group, F. W. (2021). Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. New England Journal of Medicine, 385(5), 427–435. https://doi.org/10.1056/NEJMoa2102047CrossRefPubMed

56.

Davies, K. E., & Chamberlain, J. S. (2019). Surrogate gene therapy for muscular dystrophy. Nature Medicine, 25(10), 1473–1474. https://doi.org/10.1038/s41591-019-0604-2CrossRefPubMed

57.

Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Pena, L. D. M., Shieh, P. B., Smith, E. C., Kwon, J. M., Zaidman, C. M., Schultz, M., Feltner, D. E., Tauscher-Wisniewski, S., Ouyang, H., Chand, D. H., Sproule, D. M., … Mendell, J. R. (2021). Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, 20(4), 284–293. https://doi.org/10.1016/S1474-4422(21)00001-6CrossRefPubMed

58.

Day, J. W., Finkel, R. S., Mercuri, E., Swoboda, K. J., Menier, M., van Olden, R., Tauscher-Wisniewski, S., & Mendell, J. R. (2021). Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Molecular Therapy - Methods & Clinical Development, 21, 76–82. https://doi.org/10.1016/j.omtm.2021.02.014CrossRef

59.

De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W. L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., Butterfield, R. J., Topaloglu, H., Ben-Omran, T., Sansone, V. A., Jong, Y. J., Shu, F., Staropoli, J. F., Kerr, D., Sandrock, A. W., … Group, N. S. (2019). Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscular Disorders, 29(11), 842–856. https://doi.org/10.1016/j.nmd.2019.09.007CrossRefPubMedPubMedCentral

60.

DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G. Y., Karydas, A., Seeley, W. W., Josephs, K. A., Coppola, G., Geschwind, D. H., … Rademakers, R. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Neuron, 72(2), 245–256. https://doi.org/10.1016/j.neuron.2011.09.011CrossRefPubMedPubMedCentral

61.

Deng, H., Gao, K., & Jankovic, J. (2014). The role of FUS gene variants in neurodegenerative diseases [Research Support, Non-U.S. Gov’t Review]. Nature Reviews Neurology, 10(6), 337–348. https://doi.org/10.1038/nrneurol.2014.78CrossRefPubMed

62.

Deng, H. X., Hentati, A., Tainer, J. A., Iqbal, Z., Cayabyab, A., Hung, W. Y., Getzoff, E. D., Hu, P., Herzfeldt, B., & Roos, R. P. (1993). Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science, 261(5124), 1047–1051.PubMedCrossRef

63.

Deveuve, Q., Lajoie, L., Barrault, B., & Thibault, G. (2020). The proteolytic cleavage of therapeutic monoclonal antibody hinge region: More than a matter of subclass. Frontiers in Immunology, 11, 168. https://doi.org/10.3389/fimmu.2020.00168CrossRefPubMedPubMedCentral

64.

Dimitriadi, M., Derdowski, A., Kalloo, G., Maginnis, M. S., O’Hern, P., Bliska, B., Sorkac, A., Nguyen, K. C., Cook, S. J., Poulogiannis, G., Atwood, W. J., Hall, D. H., & Hart, A. C. (2016). Decreased function of survival motor neuron protein impairs endocytic pathways [Research Support, N.I.H., Extramural]. Proceedings of the National Academy of Sciences USA, 113(30), E4377-4386. https://doi.org/10.1073/pnas.1600015113CrossRef

65.

Dimitriadi, M., Sleigh, J. N., Walker, A., Chang, H. C., Sen, A., Kalloo, G., Harris, J., Barsby, T., Walsh, M. B., Satterlee, J. S., Li, C., Van Vactor, D., Artavanis-Tsakonas, S., & Hart, A. C. (2010). Conserved genes act as modifiers of invertebrate SMN loss of function defects [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. PLoS Genetics, 6(10), e1001172. https://doi.org/10.1371/journal.pgen.1001172CrossRefPubMedPubMedCentral

66.

Doktor, T. K., Hua, Y., Andersen, H. S., Broner, S., Liu, Y. H., Wieckowska, A., Dembic, M., Bruun, G. H., Krainer, A. R., & Andresen, B. S. (2017). RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns. Nucleic Acids Research, 45(1), 395–416. https://doi.org/10.1093/nar/gkw731CrossRefPubMed

67.

Dombert, B., Balk, S., Luningschror, P., Moradi, M., Sivadasan, R., Saal-Bauernschubert, L., & Jablonka, S. (2017). BDNF/trkB induction of calcium transients through Cav2.2 calcium channels in motoneurons corresponds to F-actin assembly and growth cone formation on beta2-Chain Laminin (221). Frontiers in Molecular Neuroscience, 10, 346. https://doi.org/10.3389/fnmol.2017.00346CrossRefPubMedPubMedCentral

68.

Dombert, B., Sivadasan, R., Simon, C. M., Jablonka, S., & Sendtner, M. (2014). Presynaptic localization of Smn and hnRNP R in axon terminals of embryonic and postnatal mouse motoneurons. PLoS ONE, 9(10), e11046.CrossRef

69.

Dubowitz, V. (1964). Infantile muscular atrophy. A prospective study with particular reference to a slowly progressive variety. Brain, 87, 707–718. https://doi.org/10.1093/brain/87.4.707CrossRefPubMed

70.

Dubowitz, V. (1995). Chaos in the classification of SMA: A possible resolution. Neuromuscular Disorders, 5(1), 3–5.PubMedCrossRef

71.

Echaniz-Laguna, A., Miniou, P., Bartholdi, D., & Melki, J. (1999). The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. American Journal of Human Genetics, 64(5), 1365–1370.PubMedPubMedCentralCrossRef

72.

Echevarria, L., Aupy, P., & Goyenvalle, A. (2018). Exon-skipping advances for Duchenne muscular dystrophy [Research Support, Non-U.S. Gov’t Review]. Human Molecular Genetics, 27(R2), R163–R172. https://doi.org/10.1093/hmg/ddy171CrossRefPubMed

73.

Echigoya, Y., Lim, K. R. Q., Melo, D., Bao, B., Trieu, N., Mizobe, Y., Maruyama, R., Mamchaoui, K., Tanihata, J., Aoki, Y., Takeda, S., Mouly, V., Duddy, W., & Yokota, T. (2019). Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene [Research Support, Non-U.S. Gov’t]. Molecular Therapy, 27(11), 2005–2017. https://doi.org/10.1016/j.ymthe.2019.07.012CrossRefPubMedPubMedCentral

74.

Echigoya, Y., Lim, K. R. Q., Nakamura, A., & Yokota, T. (2018). Multiple exon skipping in the Duchenne muscular dystrophy hot spots: Prospects and challenges [review]. Journal of Personalized Medicine, 8(4), 41. https://doi.org/10.3390/jpm8040041CrossRefPubMedCentral

75.

Elangkovan, N., & Dickson, G. (2021). Gene therapy for Duchenne muscular dystrophy. Journal of Neuromuscular Diseases. https://doi.org/10.3233/JND-210678CrossRefPubMedPubMedCentral

76.

Elden, A. C., Kim, H. J., Hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M. M., Padmanabhan, A., Clay-Falcone, D., McCluskey, L., Elman, L., Juhr, D., Gruber, P. J., Rub, U., Auburger, G., Trojanowski, J. Q., … Gitler, A. D. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 466(7310), 1069–1075. https://doi.org/10.1038/nature09320CrossRefPubMedPubMedCentral

77.

Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscular Disorders, 1(1), 19–29.PubMedCrossRef

78.

Emery, A. E., Hausmanowa-Petrusewicz, I., Davie, A. M., Holloway, S., Skinner, R., & Borkowska, J. (1976). International collaborative study of the spinal muscular atrophies. Part 1. Analysis of clinical and laboratory data. Journal of the Neurological Sciences, 29(1), 83–94. https://doi.org/10.1016/0022-510x(76)90082-4CrossRefPubMed

79.

England, S. B., Nicholson, L. V., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 343(6254), 180–182. https://doi.org/10.1038/343180a0CrossRefPubMed

80.

Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C. W., Tanner, C., & Marek, K. (2004). Levodopa and the progression of Parkinson’s disease [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.]. New England Journal of Medicine, 351(24), 2498–2508. https://doi.org/10.1056/NEJMoa033447CrossRefPubMed

81.

Fallini, C., Bassell, G. J., & Rossoll, W. (2012). Spinal muscular atrophy: The role of SMN in axonal mRNA regulation. Brain Research, 1462, 81–92.PubMedPubMedCentralCrossRef

82.

Fallini, C., Zhang, H., Su, Y., Silani, V., Singer, R. H., Rossoll, W., & Bassell, G. J. (2011). The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. Journal of Neuroscience, 31(10), 3914–3925.PubMedCrossRef

83.

Farrar, M. A., Teoh, H. L., Carey, K. A., Cairns, A., Forbes, R., Herbert, K., Holland, S., Jones, K. J., Menezes, M. P., Morrison, M., Munro, K., Villano, D., Webster, R., Woodcock, I. R., Yiu, E. M., Sampaio, H., & Ryan, M. M. (2018). Nusinersen for SMA: expanded access programme [Multicenter Study Research Support, Non-U.S. Gov’t]. Journal of Neurology, Neurosurgery & Psychiatry, 89(9), 937–942. https://doi.org/10.1136/jnnp-2017-317412CrossRef

84.

Feinstein, B., Lindegard, B., Nyman, E., & Wohlfart, G. (1955). Morphologic studies of motor units in normal human muscles. Acta Anatomica (Basel), 23(2), 127–142. https://doi.org/10.1159/000140989CrossRef

85.

Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002). Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy [Research Support, Non-U.S. Gov’t]. The American Journal of Human Genetics, 70(2), 358–368. https://doi.org/10.1086/338627CrossRefPubMed

86.

Feng, Z., Ling, K. K., Zhao, X., Zhou, C., Karp, G., Welch, E. M., Naryshkin, N., Ratni, H., Chen, K. S., Metzger, F., Paushkin, S., Weetall, M., & Ko, C. P. (2016). Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics, 25(5), 964–975. https://doi.org/10.1093/hmg/ddv629CrossRefPubMed

87.

Fidzianska, A., Goebel, H. H., & Warlo, I. (1990). Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism. Brain, 113(Pt 2), 433–445. https://doi.org/10.1093/brain/113.2.433CrossRefPubMed

88.

Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., Norris, D. A., Xia, S., Bennett, C. F., & Bishop, K. M. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study [Clinical Trial, Phase II Research Support, Non-U.S. Gov’t]. Lancet, 388(10063), 3017–3026. https://doi.org/10.1016/S0140-6736(16)31408-8CrossRefPubMed

89.

Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., … Group, E. S. (2017). Nusinersen versus Sham control in infantile-onset spinal muscular atrophy [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial]. New England Journal of Medicine, 377(18), 1723–1732. https://doi.org/10.1056/NEJMoa1702752CrossRefPubMed

90.

Finkel, R. S., Day, J. W., Darras, B. T., Kuntz, N. L., Connolly, A. M., et al. (2019). Phase 1 study of intrathecal administration of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2) (STRONG) (P1.6-059). Neurology, 92, P1.6-059.

91.

Fischer, U., Liu, Q., & Dreyfuss, G. (1997). The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 77(5), 727–736, 90(6), 1023–1029.

92.

Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Biotechnology, 27(1), 59–65. https://doi.org/10.1038/nbt.1515CrossRefPubMed

93.

Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H., & Kaspar, B. K. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology, 28(3), 271–274.PubMedPubMedCentralCrossRef

94.

Freibaum, B. D., & Taylor, J. P. (2017). The role of dipeptide repeats in C9ORF72-related ALS-FTD [review]. Frontiers in Molecular Neuroscience, 10, 35. https://doi.org/10.3389/fnmol.2017.00035CrossRefPubMedPubMedCentral

95.

Fujii, R., Okabe, S., Urushido, T., Inoue, K., Yoshimura, A., Tachibana, T., Nishikawa, T., Hicks, G. G., & Takumi, T. (2005). The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Current Biology, 15(6), 587–593. https://doi.org/10.1016/j.cub.2005.01.058CrossRefPubMed

96.

Fujii, R., & Takumi, T. (2005). TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines [Research Support, Non-U.S. Gov’t]. Journal of Cell Science, 118(Pt 24), 5755–5765. https://doi.org/10.1242/jcs.02692CrossRefPubMed

97.

Gabanella, F., Carissimi, C., Usiello, A., & Pellizzoni, L. (2005). The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation [Research Support, Non-U.S. Gov’t]. Human Molecular Genetics, 14(23), 3629–3642. https://doi.org/10.1093/hmg/ddi390CrossRefPubMed

98.

Garcia, E. L., Lu, Z., Meers, M. P., Praveen, K., & Matera, A. G. (2013). Developmental arrest of Drosophila survival motor neuron (Smn) mutants accounts for differences in expression of minor intron-containing genes. RNA, 19(11), 1510–1516.PubMedPubMedCentralCrossRef

99.

Gavrilina, T. O., McGovern, V. L., Workman, E., Crawford, T. O., Gogliotti, R. G., DiDonato, C. J., Monani, U. R., Morris, G. E., & Burghes, A. H. (2008). Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Human Molecular Genetics, 17(8), 1063–1075. https://doi.org/10.1093/hmg/ddm379CrossRefPubMed

100.

Gidaro, T., & Servais, L. (2019). Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps [Review]. Developmental Medicine and Child Neurology, 61(1), 19–24. https://doi.org/10.1111/dmcn.14027CrossRefPubMed

101.

Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., Qi, L. S., Kampmann, M., & Weissman, J. S. (2014). Genome-scale CRISPR-mediated control of gene repression and activation [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Cell, 159(3), 647–661. https://doi.org/10.1016/j.cell.2014.09.029CrossRefPubMedPubMedCentral

102.

Glinka, M., Herrmann, T., Funk, N., Havlicek, S., Rossoll, W., Winkler, C., & Sendtner, M. (2010). The heterogeneous nuclear ribonucleoprotein-R is necessary for axonal beta-actin mRNA translocation in spinal motor neurons. Human Molecular Genetics, 19(10), 1951–1966.PubMedCrossRef

103.

Gogliotti, R. G., Quinlan, K. A., Barlow, C. B., Heier, C. R., Heckman, C. J., & Didonato, C. J. (2012). Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. Journal of Neuroscience, 32(11), 3818–3829. https://doi.org/10.1523/JNEUROSCI.5775-11.2012CrossRefPubMed

104.

Gopal, P. P., Nirschl, J. J., Klinman, E., & Holzbaur, E. L. (2017). Amyotrophic lateral sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. Proceedings of the National Academy of Sciences USA, 114(12), E2466–E2475. https://doi.org/10.1073/pnas.1614462114CrossRef

105.

Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.]. Nature, 432(7014), 235–240. https://doi.org/10.1038/nature03120CrossRefPubMed

106.

Grohmann, K., Rossoll, W., Kobsar, I., Holtmann, B., Jablonka, S., Wessig, C., Stoltenburg-Didinger, G., Fischer, U., Hubner, C., Martini, R., & Sendtner, M. (2004). Characterization of Ighmbp2 in motor neurons and implications for the pathomechanism in a mouse model of human spinal muscular atrophy with respiratory distress type 1 (SMARD1). Human Molecular Genetics, 13(18), 2031–2042.PubMedCrossRef

107.

Grohmann, K., Schuelke, M., Diers, A., Hoffmann, K., Lucke, B., Adams, C., Bertini, E., Leonhardt-Horti, H., Muntoni, F., Ouvrier, R., Pfeufer, A., Rossi, R., Van Maldergem, L., Wilmshurst, J. M., Wienker, T. F., Sendtner, M., Rudnik-Schoneborn, S., Zerres, K., & Hubner, C. (2001). Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nature Genetics, 29(1), 75–77.PubMedCrossRef

108.

Grohmann, K., Varon, R., Stolz, P., Schuelke, M., Janetzki, C., Bertini, E., Bushby, K., Muntoni, F., Ouvrier, R., Van Maldergem, L., Goemans, N. M., Lochmuller, H., Eichholz, S., Adams, C., Bosch, F., Grattan-Smith, P., Navarro, C., Neitzel, H., Polster, T., … Hubner, C. (2003). Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Annals of Neurology, 54(6), 719–724. (IN FILE).PubMedCrossRef

109.

Grohmann, K., Wienker, T. F., Saar, K., Rudnik-Schoneborn, S., Stoltenburg-Didinger, G., Rossi, R., Novelli, G., Nurnberg, G., Pfeufer, A., Wirth, B., Reis, A., Zerres, K., & Hubner, C. (1999). Diaphragmatic spinal muscular atrophy with respiratory distress is heterogeneous, and one form Is linked to chromosome 11q13-q21. American Journal of Human Genetics, 65(5), 1459–1462.PubMedPubMedCentralCrossRef

110.

Guo, W., Naujock, M., Fumagalli, L., Vandoorne, T., Baatsen, P., Boon, R., Ordovas, L., Patel, A., Welters, M., Vanwelden, T., Geens, N., Tricot, T., Benoy, V., Steyaert, J., Lefebvre-Omar, C., Boesmans, W., Jarpe, M., Sterneckert, J., Wegner, F., … Van Den Bosch, L. (2017). HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nature Communications, 8(1), 861. https://doi.org/10.1038/s41467-017-00911-yCrossRefPubMedPubMedCentral

111.

Hagenacker, T., Wurster, C. D., Gunther, R., Schreiber-Katz, O., Osmanovic, A., Petri, S., Weiler, M., Ziegler, A., Kuttler, J., Koch, J. C., Schneider, I., Wunderlich, G., Schloss, N., Lehmann, H. C., Cordts, I., Deschauer, M., Lingor, P., Kamm, C., Stolte, B., … Kleinschnitz, C. (2020). Nusinersen in adults with 5q spinal muscular atrophy: A non-interventional, multicentre, observational cohort study. Lancet Neurology, 19(4), 317–325. https://doi.org/10.1016/S1474-4422(20)30037-5CrossRefPubMed

112.

Hamilton, G., & Gillingwater, T. H. (2013). Spinal muscular atrophy: Going beyond the motor neuron [Review]. Trends in Molecular Medicine, 19(1), 40–50. https://doi.org/10.1016/j.molmed.2012.11.002CrossRefPubMed

113.

le Hao, T., Wolman, M., Granato, M., & Beattie, C. E. (2012). Survival motor neuron affects plastin 3 protein levels leading to motor defects. Journal of Neuroscience, 32(15), 5074–5084. https://doi.org/10.1523/JNEUROSCI.5808-11.2012CrossRef

114.

Hayhurst, M., Wagner, A. K., Cerletti, M., Wagers, A. J., & Rubin, L. L. (2012). A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein. Developmental Biology, 368(2), 323–334. https://doi.org/10.1016/j.ydbio.2012.05.037CrossRefPubMed

115.

Heckman, C. J. & Enoka, R. M. (2004). Physiology of the motor neuron and the motor unit, clinical neurophysiology of motor neuron diseases. In Handbook of clinical neurophysiology, Vol. 4, Chapter 6.

116.

Henderson, C. E., Phillips, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M., Simpson, L. C., Moffet, B., Vandlen, R. A., Koliatsos, V. E., & Rosenthal, A. (1994). GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science, 266, 1062–1064.PubMedCrossRef

117.

High-dose AAV gene therapy deaths. (2020, 2020/08/01). Nature Biotechnology, 38(8), 910. https://doi.org/10.1038/s41587-020-0642-9

118.

Hill, J. J., Davies, M. V., Pearson, A. A., Wang, J. H., Hewick, R. M., Wolfman, N. M., & Qiu, Y. (2002). The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. Journal of Biological Chemistry, 277(43), 40735–40741. https://doi.org/10.1074/jbc.M206379200CrossRefPubMed

119.

Himic, V., & Davies, K. E. (2021). Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy. European Journal of Human Genetics. https://doi.org/10.1038/s41431-021-00811-2CrossRefPubMedPubMedCentral

120.

Hinderer, C., Miller, R., Dyer, C., Johansson, J., Bell, P., Buza, E., & Wilson, J. M. (2020). Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations. Annals of Clinical Translational Neurology, 7(10), 1843–1853. https://doi.org/10.1002/acn3.51165CrossRefPubMedPubMedCentral

121.

Hoell, J. I., Larsson, E., Runge, S., Nusbaum, J. D., Duggimpudi, S., Farazi, T. A., Hafner, M., Borkhardt, A., Sander, C., & Tuschl, T. (2011). RNA targets of wild-type and mutant FET family proteins [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Structural & Molecular Biology, 18(12), 1428–1431. https://doi.org/10.1038/nsmb.2163CrossRef

122.

Hoffmann, J. (1893). Ueber chronische spinal Muskelatrophie im Kindesalter, auf familiärer Basis. Deutsche Zeitschrift für Nervenheilkunde, 3, 427.CrossRef

123.

Hoffmann, J. (1897). Weiterer Beitrag zur Lehre von der hereditären progressiven spinalen Muskelatrophie im Kindesalter. Deutsche Zeitschrift für Nervenheilkunde, 10, 13.

124.

Hosseinibarkooie, S., Peters, M., Torres-Benito, L., Rastetter, R. H., Hupperich, K., Hoffmann, A., Mendoza-Ferreira, N., Kaczmarek, A., Janzen, E., Milbradt, J., Lamkemeyer, T., Rigo, F., Bennett, C. F., Guschlbauer, C., Buschges, A., Hammerschmidt, M., Riessland, M., Kye, M. J., Clemen, C. S., & Wirth, B. (2016). The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. The American Journal of Human Genetics, 99(3), 647–665.PubMedCrossRef

125.

Hoy, S. M. (2019). Onasemnogene Abeparvovec: First global approval [review]. Drugs, 79(11), 1255–1262. https://doi.org/10.1007/s40265-019-01162-5CrossRefPubMed

126.

Hsieh-Li, H. M., Chang, J. G., Jong, Y. J., Wu, M. H., Wang, N. M., Tsai, C. H., & Li, H. (2000). A mouse model for spinal muscular atrophy. Nature Genetics, 24(1), 66–70.PubMedCrossRef

127.

Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011). Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 377(6547), 340–344, 478(7367), 123–126.

128.

Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008). Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The American Journal of Human Genetics, 82(4), 834–848. https://doi.org/10.1016/j.ajhg.2008.01.014CrossRefPubMed

129.

Hughes, R. A., Sendtner, M., Goldfarb, M., Lindholm, D., & Thoenen, H. (1993). Evidence that fibroblast growth factor 5 is a major muscle derived survival factor for cultured spinal motoneurons. Neuron, 10, 369–377. (IN FILE).PubMedCrossRef

130.

Hwee, D. T., Kennedy, A. R., Hartman, J. J., Ryans, J., Durham, N., Malik, F. I., & Jasper, J. R. (2015). The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure [Research Support, Non-U.S. Gov’t]. Journal of Pharmacology and Experimental Therapeutics, 353(1), 159–168. https://doi.org/10.1124/jpet.114.222224CrossRefPubMed

131.

Imbert, G., Saudou, F., Yvert, G., Devys, D., Trottier, Y., Garnier, J. M., Weber, C., Mandel, J. L., Cancel, G., Abbas, N., Durr, A., Didierjean, O., Stevanin, G., Agid, Y., & Brice, A. (1996). Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nature Genetics, 14(3), 285–291. https://doi.org/10.1038/ng1196-285CrossRefPubMed

132.

Imlach, W. L., Beck, E. S., Choi, B. J., Lotti, F., Pellizzoni, L., & McCabe, B. D. (2012). SMN is required for sensory-motor circuit function in Drosophila. Cell 77(5), 727–736, 151(2), 427–439.

133.

Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegenerative disease: The story so far [Review]. Nature Reviews. Neurology, 12(1), 15–27. https://doi.org/10.1038/nrneurol.2015.225CrossRefPubMed

134.

Ishigaki, S., Fujioka, Y., Okada, Y., Riku, Y., Udagawa, T., Honda, D., Yokoi, S., Endo, K., Ikenaka, K., Takagi, S., Iguchi, Y., Sahara, N., Takashima, A., Okano, H., Yoshida, M., Warita, H., Aoki, M., Watanabe, H., Okado, H., … Sobue, G. (2017). Altered Tau isoform ratio caused by loss of FUS and SFPQ function leads to FTLD-like phenotypes. Cell Reports, 18(5), 1118–1131. https://doi.org/10.1016/j.celrep.2017.01.013CrossRefPubMed

135.

Ishigaki, S., Masuda, A., Fujioka, Y., Iguchi, Y., Katsuno, M., Shibata, A., Urano, F., Sobue, G., & Ohno, K. (2012). Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions [Research Support, Non-U.S. Gov’t]. Scientific Reports, 2, 529. https://doi.org/10.1038/srep00529CrossRefPubMedPubMedCentral

136.

Ittner, A., Asih, P. R., Tan, A. R. P., Prikas, E., Bertz, J., Stefanoska, K., Lin, Y., Volkerling, A. M., Ke, Y. D., Delerue, F., & Ittner, L. M. (2020). Reduction of advanced tau-mediated memory deficits by the MAP kinase p38gamma [Research Support, Non-US Gov’t]. Acta Neuropathologica, 140(3), 279–294. https://doi.org/10.1007/s00401-020-02191-1CrossRefPubMed

137.

Iyer, C. C., McGovern, V. L., Murray, J. D., Gombash, S. E., Zaworski, P. G., Foust, K. D., Janssen, P. M., & Burghes, A. H. (2015). Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNDelta7 mouse model of SMA. Human Molecular Genetics, 24(21), 6160–6173. https://doi.org/10.1093/hmg/ddv332CrossRefPubMedPubMedCentral

138.

Jablonka, S., Bandilla, M., Wiese, S., Buhler, D., Wirth, B., Sendtner, M., & Fischer, U. (2001). Co-regulation of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in spinal muscular atrophy. Human Molecular Genetics, 10(5), 497–505. https://doi.org/10.1093/hmg/10.5.497CrossRefPubMed

139.

Jablonka, S., Beck, M., Lechner, B. D., Mayer, C., & Sendtner, M. (2007). Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy. Journal of Cell Biology, 179(1), 139–149. (IN FILE).PubMedPubMedCentralCrossRef

140.

Jablonka, S., Schrank, B., Kralewski, M., Rossoll, W., & Sendtner, M. (2000). Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III [Research Support, Non-U.S. Gov’t]. Human Molecular Genetics, 9(3), 341–346. https://doi.org/10.1093/hmg/9.3.341CrossRefPubMed

141.

Jablonka, S., & Sendtner, M. (2017). Developmental regulation of SMN expression: Pathophysiological implications and perspectives for therapy development in spinal muscular atrophy [Review]. Gene Therapy. https://doi.org/10.1038/gt.2017.46CrossRefPubMed

142.

Jablonka, S., Wiese, S., & Sendtner, M. (2004). Axonal defects in mouse models of motoneuron disease. Journal of Neurobiology, 58(2), 272–286.PubMedCrossRef

143.

Janzen, E., Mendoza-Ferreira, N., Hosseinibarkooie, S., Schneider, S., Hupperich, K., Tschanz, T., Grysko, V., Riessland, M., Hammerschmidt, M., Rigo, F., Bennett, C. F., Kye, M. J., Torres-Benito, L., & Wirth, B. (2018). CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis [Research Support, Non-U.S. Gov’t]. Brain, 141(8), 2343–2361. https://doi.org/10.1093/brain/awy167CrossRefPubMedPubMedCentral

144.

Ji, C., Bader, J., Ramanathan, P., Hennlein, L., Meissner, F., Jablonka, S., Mann, M., Fischer, U., Sendtner, M., & Briese, M. (2021). Interaction of 7SK with the Smn complex modulates snRNP production [Research Support, Non-U.S. Gov’t]. Nature Communications, 12(1), 1278. https://doi.org/10.1038/s41467-021-21529-1CrossRefPubMedPubMedCentral

145.

Kapeli, K., Pratt, G. A., Vu, A. Q., Hutt, K. R., Martinez, F. J., Sundararaman, B., Batra, R., Freese, P., Lambert, N. J., Huelga, S. C., Chun, S. J., Liang, T. Y., Chang, J., Donohue, J. P., Shiue, L., Zhang, J., Zhu, H., Cambi, F., Kasarskis, E., … Yeo, G. W. (2016). Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Nature Communications, 7, 12143. https://doi.org/10.1038/ncomms12143CrossRefPubMedPubMedCentral

146.

Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., & During, M. J. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial [Clinical Trial, Phase I Research Support, Non-U.S. Gov’t]. Lancet, 369(9579), 2097–2105. https://doi.org/10.1016/S0140-6736(07)60982-9CrossRefPubMed

147.

Kariya, S., Obis, T., Garone, C., Akay, T., Sera, F., Iwata, S., Homma, S., & Monani, U. R. (2014). Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Journal of Clinical Investigation, 124(2), 785–800. https://doi.org/10.1172/JCI72017CrossRefPubMedPubMedCentral

148.

Kato, A. C., & Lindsay, R. M. (1994). Overlapping and additive effects of neurotrophins and CNTF on cultured human spinal cord neurons. Experimental Neurology, 130, 196–201.PubMedCrossRef

149.

Kernochan, L. E., Russo, M. L., Woodling, N. S., Huynh, T. N., Avila, A. M., Fischbeck, K. H., & Sumner, C. J. (2005). The role of histone acetylation in SMN gene expression. Human Molecular Genetics, 14(9), 1171–1182.PubMedCrossRef

150.

Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020). ALS genetics: Gains, losses, and implications for future therapies [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Review]. Neuron, 108(5), 822–842. https://doi.org/10.1016/j.neuron.2020.08.022CrossRefPubMedPubMedCentral

151.

Kim, J. K., Jha, N. N., Feng, Z., Faleiro, M. R., Chiriboga, C. A., Wei-Lapierre, L., Dirksen, R. T., Ko, C. P., & Monani, U. R. (2020). Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. The Journal of Clinical Investigation, 130(3), 1271–1287. https://doi.org/10.1172/JCI131989CrossRefPubMedPubMedCentral

152.

Klein, R., Jing, S., Nanduri, V., O'Rourke, E., & Barbacid, M. (1991). The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 77(5), 727–736, 65, 189–197.

153.

Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991). The trk B tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 77(5), 727–736, 66, 395–403.

154.

Klein, R., Parada, L. F., Coulier, F., & Barbacid, M. (1989). trk B, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO Journal, 8, 3701–3709. (IN FILE).PubMedPubMedCentralCrossRef

155.

Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Muller, C. R., Lindlof, M., Kaariainen, H., de la Chapellet, A., Kiuru, A., Savontaus, M. L., Gilgenkrantz, H., Recan, D., Chelly, J., Kaplan, J. C., Covone, A. E., Archidiacono, N., … Kunkel, L. M. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. American Journal of Human Genetics, 45(4), 498–506.PubMedPubMedCentral

156.

Kong, L., Valdivia, D. O., Simon, C. M., Hassinan, C. W., Delestree, N., Ramos, D. M., Park, J. H., Pilato, C. M., Xu, X., Crowder, M., Grzyb, C. C., King, Z. A., Petrillo, M., Swoboda, K. J., Davis, C., Lutz, C. M., Stephan, A. H., Zhao, X., Weetall, M., … Sumner, C. J. (2021). Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abb6871CrossRefPubMedPubMedCentral

157.

Kong, L., Wang, X., Choe, D. W., Polley, M., Burnett, B. G., Bosch-Marce, M., Griffin, J. W., Rich, M. M., & Sumner, C. J. (2009). Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. Journal of Neuroscience, 29(3), 842–851.PubMedCrossRef

158.

Krieger, F., Elflein, N., Ruiz, R., Guerra, J., Serrano, A. L., Asan, E., Tabares, L., & Jablonka, S. (2013). Fast motor axon loss in SMARD1 does not correspond to morphological and functional alterations of the NMJ. Neurobiology of Disease, 54, 169–182.PubMedCrossRef

159.

Krieger, F., Elflein, N., Saenger, S., Wirthgen, E., Rak, K., Frantz, S., Hoeflich, A., Toyka, K. V., Metzger, F., & Jablonka, S. (2014). Polyethylene glycol-coupled IGF1 delays motor function defects in a mouse model of spinal muscular atrophy with respiratory distress type 1. Brain, 137(Pt 5), 1374–1393.PubMedCrossRef

160.

Kugelberg, E., & Welander, L. (1956). Heredofamilial juvenile muscular atrophy simulating muscular dystrophy. Archives of Neurology, 75, 500.CrossRef

161.

Kumar, V., Hasan, G. M., & Hassan, M. I. (2017). Unraveling the role of RNA mediated toxicity of C9orf72 repeats in C9-FTD/ALS [Review]. Frontiers in Neuroscience, 11, 711. https://doi.org/10.3389/fnins.2017.00711CrossRefPubMedPubMedCentral

162.

Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., Valdmanis, P., Rouleau, G. A., Hosler, B. A., Cortelli, P., de Jong, P. J., Yoshinaga, Y., Haines, J. L., Pericak-Vance, M. A., Yan, J., … Brown, R. H., Jr. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323(5918), 1205–1208. https://doi.org/10.1126/science.1166066CrossRefPubMed

163.

Kwon, I., Xiang, S., Kato, M., Wu, L., Theodoropoulos, P., Wang, T., Kim, J., Yun, J., Xie, Y., & McKnight, S. L. (2014). Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells [Research Support, Non-U.S. Gov’t]. Science, 345(6201), 1139–1145. https://doi.org/10.1126/science.1254917CrossRefPubMedPubMedCentral

164.

Lagier-Tourenne, C., Polymenidou, M., Hutt, K. R., Vu, A. Q., Baughn, M., Huelga, S. C., Clutario, K. M., Ling, S. C., Liang, T. Y., Mazur, C., Wancewicz, E., Kim, A. S., Watt, A., Freier, S., Hicks, G. G., Donohue, J. P., Shiue, L., Bennett, C. F., Ravits, J., … Yeo, G. W. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature Neurosciences, 15(11), 1488–1497. https://doi.org/10.1038/nn.3230CrossRef

165.

Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., Francois, V., Dutilleul, M., Malerba, A., Koo, T., Thibaut, J. L., Matot, B., Devaux, M., Le Duff, J., Deschamps, J. Y., Barthelemy, I., Blot, S., Testault, I., … Dickson, G. (2017). Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy [Research Support, Non-U.S. Gov’t]. Nature Communications, 8, 16105. https://doi.org/10.1038/ncomms16105CrossRefPubMedPubMedCentral

166.

Le, T. T., Pham, L. T., Butchbach, M. E., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. (2005). SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Human Molecular Genetics, 14(6), 845–857.PubMedCrossRef

167.

Lee, J., Echigoya, Y., Duddy, W., Saito, T., Aoki, Y., Takeda, S., & Yokota, T. (2018). Antisense PMO cocktails effectively skip dystrophin exons 45–55 in myotubes transdifferentiated from DMD patient fibroblasts [Research Support, Non-U.S. Gov’t]. PLoS ONE, 13(5), e0197084. https://doi.org/10.1371/journal.pone.0197084CrossRefPubMedPubMedCentral

168.

Lee, K. H., Zhang, P., Kim, H. J., Mitrea, D. M., Sarkar, M., Freibaum, B. D., Cika, J., Coughlin, M., Messing, J., Molliex, A., Maxwell, B. A., Kim, N. C., Temirov, J., Moore, J., Kolaitis, R. M., Shaw, T. I., Bai, B., Peng, J., Kriwacki, R. W., & Taylor, J. P. (2016). C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Cell, 167(3), 774–788717. https://doi.org/10.1016/j.cell.2016.10.002CrossRefPubMedPubMedCentral

169.

Lee, S. J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences USA, 98(16), 9306–9311. https://doi.org/10.1073/pnas.151270098CrossRef

170.

Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., & et al. (1995). Identification and characterization of a spinal muscular atrophy- determining gene [see comments]. Cell 77(5), 727–36, 80(1), 155–165.

171.

LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., Tatter, S. B., Schwalb, J. M., Poston, K. L., Henderson, J. M., Kurlan, R. M., Richard, I. H., Van Meter, L., Sapan, C. V., During, M. J., … Feigin, A. (2011). AAV2-GAD gene therapy for advanced Parkinson’s disease: A double-blind, sham-surgery controlled, randomised trial [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. The Lancet Neurology, 10(4), 309–319. https://doi.org/10.1016/S1474-4422(11)70039-4CrossRefPubMed

172.

Li, L., Oppenheim, R. W., Lei, M., & Houenou, L. J. (1994). Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. Journal of Neurobiology, 25, 759–766. (IN FILE).PubMedCrossRef

173.

Lichtman, J. W., & Colman, H. (2000). Synapse elimination and indelible memory. Neuron, 25(2), 269–278. https://doi.org/10.1016/s0896-6273(00)80893-4CrossRefPubMed

174.

Ling, K. K., Gibbs, R. M., Feng, Z., & Ko, C. P. (2012). Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Human Molecular Genetics, 21(1), 185–195.PubMedCrossRef

175.

Liou, J. C., Yang, R. S., & Fu, W. M. (1997). Regulation of quantal secretion by neurotrophic factors at developing motoneurons in xenopus cell cultures. Journal of Physiology (London), 503, 129–139.CrossRef

176.

Liu, Q., & Dreyfuss, G. (1996). A novel nuclear structure containing the survival of motor neurons protein. EMBO Journal, 15, 3555–3565.PubMedPubMedCentralCrossRef

177.

Liu, Q., Fischer, U., Wang, F., & Dreyfuss, G. (1997). The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 77(5), 727–736, 90(6), 1013–1021.

178.

Loboda, A., & Dulak, J. (2020). Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: Past, present, and future. Pharmacological Reports, 72(5), 1227–1263. https://doi.org/10.1007/s43440-020-00134-xCrossRefPubMedPubMedCentral

179.

Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E., Buckler, A., & Donovan, A. (2019). Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Human Molecular Genetics, 28(7), 1076–1089. https://doi.org/10.1093/hmg/ddy382CrossRefPubMed

180.

Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National academy of Sciences of the United States of America, 96(11), 6307–6311.PubMedPubMedCentralCrossRef

181.

Lotti, F., Imlach, W. L., Saieva, L., Beck, E. S., le Hao, T., Li, D. K., Jiao, W., Mentis, G. Z., Beattie, C. E., McCabe, B. D., & Pellizzoni, L. (2012). An SMN-dependent U12 splicing event essential for motor circuit function [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Cell, 151(2), 440–454. https://doi.org/10.1016/j.cell.2012.09.012CrossRefPubMedPubMedCentral

182.

Lundin, K. E., Gissberg, O., & Smith, C. I. (2015). Oligonucleotide therapies: The past and the present. Human Gene Therapy, 26(8), 475–485. https://doi.org/10.1089/hum.2015.070CrossRefPubMedPubMedCentral

183.

Lutz, C. M., Kariya, S., Patruni, S., Osborne, M. A., Liu, D., Henderson, C. E., Li, D. K., Pellizzoni, L., Rojas, J., Valenzuela, D. M., Murphy, A. J., Winberg, M. L., & Monani, U. R. (2011). Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of Clinical Investigation, 121(8), 3029–3041. https://doi.org/10.1172/JCI57291CrossRefPubMedPubMedCentral

184.

Maggi, L., Bello, L., Bonanno, S., Govoni, A., Caponnetto, C., Passamano, L., Grandis, M., Trojsi, F., Cerri, F., Ferraro, M., Bozzoni, V., Caumo, L., Piras, R., Tanel, R., Saccani, E., Meneri, M., Vacchiano, V., Ricci, G., Soraru, G., … Pegoraro, E. (2020). Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery and Psychiatry, 91(11), 1166–1174. https://doi.org/10.1136/jnnp-2020-323822CrossRefPubMed

185.

Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H., & Prior, T. W. (2002). Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genetics in Medicine, 4(1), 20–26.PubMedCrossRef

186.

Martinez-Hernandez, R., Bernal, S., Alias, L., & Tizzano, E. F. (2014). Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy. Journal of Neuropathology and Experimental Neurology, 73(6), 559–567. https://doi.org/10.1097/NEN.0000000000000078CrossRefPubMed

187.

Martinez-Hernandez, R., Soler-Botija, C., Also, E., Alias, L., Caselles, L., Gich, I., Bernal, S., & Tizzano, E. F. (2009). The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. Journal of Neuropathology and Experimental Neurology, 68(5), 474–481. https://doi.org/10.1097/NEN.0b013e3181a10ea1CrossRefPubMed

188.

Masuda, A., Takeda, J., Okuno, T., Okamoto, T., Ohkawara, B., Ito, M., Ishigaki, S., Sobue, G., & Ohno, K. (2015). Position-specific binding of FUS to nascent RNA regulates mRNA length [Research Support, Non-U.S. Gov’t]. Genes & Development, 29(10), 1045–1057. https://doi.org/10.1101/gad.255737.114CrossRef

189.

May, S., Hornburg, D., Schludi, M. H., Arzberger, T., Rentzsch, K., Schwenk, B. M., Grasser, F. A., Mori, K., Kremmer, E., Banzhaf-Strathmann, J., Mann, M., Meissner, F., & Edbauer, D. (2014). C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration [Research Support, Non-U.S. Gov’t]. Acta Neuropathologica, 128(4), 485–503. https://doi.org/10.1007/s00401-014-1329-4CrossRefPubMedPubMedCentral

190.

McCormack, N. M., Villalon, E., Viollet, C., Soltis, A. R., Dalgard, C. L., Lorson, C. L., & Burnett, B. G. (2021). Survival motor neuron deficiency slows myoblast fusion through reduced myomaker and myomixer expression. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12740CrossRefPubMedPubMedCentral

191.

McPherron, A. C., Lawler, A. M., & Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83–90. https://doi.org/10.1038/387083a0CrossRefPubMed

192.

McWhorter, M. L., Monani, U. R., Burghes, A. H., & Beattie, C. E. (2003). Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. Journal of Cell Biology, 162(5), 919–932.PubMedPubMedCentralCrossRef

193.

Meijer, L., Borgne, A., Mulner, O., Chong, J. P., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J. G., & Moulinoux, J. P. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry, 243(1–2), 527–536.PubMedCrossRef

194.

Meister, G., Eggert, C., & Fischer, U. (2002). SMN-mediated assembly of RNPs: A complex story. Trends in Cell Biology, 12(10), 472–478.PubMedCrossRef

195.

Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., … Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy [Clinical Trial, Phase I Clinical Trial, Phase II Controlled Clinical Trial]. New England Journal of Medicine, 377(18), 1713–1722. https://doi.org/10.1056/NEJMoa1706198CrossRefPubMed

196.

Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., Shieh, P. B., Tulinius, M., Mazzone, E. S., Montes, J., Bishop, K. M., Yang, Q., Foster, R., Gheuens, S., Bennett, C. F., … Group, C. S. (2018). Nusinersen versus Sham control in later-onset spinal muscular atrophy [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. New England Journal of Medicine, 378(7), 625–635. https://doi.org/10.1056/NEJMoa1710504CrossRefPubMed

197.

Mercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E. S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R. H., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., Kirschner, J., Iannaccone, S. T., Crawford, T. O., … Group, S. M. A. C. (2018). Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care [Practice Guideline Research Support, Non-U.S. Gov’t Review]. Neuromuscular Disorders, 28(2), 103–115. https://doi.org/10.1016/j.nmd.2017.11.005CrossRefPubMed

198.

Mercuri, E., Muntoni, F., Baranello, G., Masson, R., Boespflug-Tanguy, O., Bruno, C., Corti, S., Daron, A., Deconinck, N., Servais, L., Straub, V., Ouyang, H., Chand, D., Tauscher-Wisniewski, S., Mendonca, N., Lavrov, A., & group, S. V.-E. s. (2021). Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurology, 20(10), 832–841. https://doi.org/10.1016/S1474-4422(21)00251-9CrossRefPubMed

199.

Messina, S., Pane, M., Sansone, V., Bruno, C., Catteruccia, M., Vita, G., Palermo, C., Albamonte, E., Pedemonte, M., Bertini, E., Binetti, L., Mercuri, E., & Italian, E. A. P. w. G. (2017). Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience [Editorial]. Neuromuscular Disorders, 27(12), 1084–1086. https://doi.org/10.1016/j.nmd.2017.09.006CrossRefPubMed

200.

Middlemas, D. S., Lindberg, R. A., & Hunter, T. (1991). trk B, A neural receptor protein-tyrosine kinase: Evidence for a full-length and two truncated receptors. Molecular and Cellular Biology, 11, 143–153.PubMedPubMedCentral

201.

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., Maragakis, N. J., McDermott, C. J., Pestronk, A., Ravits, J., Salachas, F., Trudell, R., Van Damme, P., Zinman, L., Bennett, C. F., … Ferguson, T. A. (2020). Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. New England Journal of Medicine, 383(2), 109–119. https://doi.org/10.1056/NEJMoa2003715CrossRefPubMed

202.

Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., Ostrow, L. W., Schoenfeld, D., Macklin, E. A., Norris, D. A., Manousakis, G., Crisp, M., Smith, R., Bennett, C. F., Bishop, K. M., & Cudkowicz, M. E. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study [Clinical Trial, Phase I Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t. The Lancet Neurology, 12(5), 435–442. https://doi.org/10.1016/S1474-4422(13)70061-9CrossRefPubMedPubMedCentral

203.

Miller, W. C., & DeLong, M. R. (1987). The Basal Ganglia II: Structure and Function. In M. B. Carpenter & A. Jayaraman (Eds.), Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate model of parkjinsonism (pp. 415–427). Plenum.

204.

Mizielinska, S., & Isaacs, A. M. (2016). Neurodegeneration. One target for amyotrophic lateral sclerosis therapy? [Comment]. Science, 353(6300), 647–648. https://doi.org/10.1126/science.aah5408CrossRefPubMed

205.

Mizielinska, S., Lashley, T., Norona, F. E., Clayton, E. L., Ridler, C. E., Fratta, P., & Isaacs, A. M. (2013). C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci [Research Support, Non-U.S. Gov’t]. Acta Neuropathologica, 126(6), 845–857. https://doi.org/10.1007/s00401-013-1200-zCrossRefPubMedPubMedCentral

206.

Monani, U. R., Lorson, C. L., Parsons, D. W., Prior, T. W., Androphy, E. J., Burghes, A. H., & McPherson, J. D. (1999). A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Human Molecular Genetics, 8(7), 1177–1183.PubMedCrossRef

207.

Monani, U. R., McPherson, J. D., & Burghes, A. H. (1999). Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT) [In Process Citation]. Biochimica et Biophysica Acta, 1445(3), 330–336.PubMedCrossRef

208.

Monani, U. R., Sendtner, M., Coovert, D. D., Parsons, D. W., Andreassi, C., Le, T. T., Jablonka, S., Schrank, B., Rossoll, W., Prior, T. W., Morris, G. E., & Burghes, A. H. (2000). The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Human Molecular Genetics, 9(3), 333–339. https://doi.org/10.1093/hmg/9.3.333CrossRefPubMed

209.

Montes, J., Dunaway Young, S., Mazzone, E. S., Pasternak, A., Glanzman, A. M., Finkel, R. S., Darras, B. T., Muntoni, F., Mercuri, E., De Vivo, D. C., Bishop, K. M., Schneider, E., Bennett, C. F., Foster, R., Farwell, W., & Groups, C. S. S. (2019). Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle and Nerve, 60(4), 409–414. https://doi.org/10.1002/mus.26633CrossRefPubMed

210.

Montes, J., McDermott, M. P., Mirek, E., Mazzone, E. S., Main, M., Glanzman, A. M., Duong, T., Young, S. D., Salazar, R., Pasternak, A., Gee, R., De Sanctis, R., Coratti, G., Forcina, N., Fanelli, L., Ramsey, D., Milev, E., Civitello, M., Pane, M., … Mercuri, E. (2018). Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS ONE, 13(6), e0199657. https://doi.org/10.1371/journal.pone.0199657CrossRefPubMedPubMedCentral

211.

Moradi, M., Sivadasan, R., Saal, L., Luningschror, P., Dombert, B., Rathod, R. J., Dieterich, D. C., Blum, R., & Sendtner, M. (2017). Differential roles of alpha-, beta-, and gamma-actin in axon growth and collateral branch formation in motoneurons. Journal of Cell Biology, 216(3), 793–814. https://doi.org/10.1083/jcb.201604117CrossRefPubMedPubMedCentral

212.

Mori, K., Weng, S. M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H. A., Cruts, M., Van Broeckhoven, C., Haass, C., & Edbauer, D. (2013). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS [Research Support, Non-U.S. Gov’t]. Science, 339(6125), 1335–1338. https://doi.org/10.1126/science.1232927CrossRefPubMed

213.

Morlando, M., Dini Modigliani, S., Torrelli, G., Rosa, A., Di Carlo, V., Caffarelli, E., & Bozzoni, I. (2012). FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment [Research Support, Non-U.S. Gov’t]. The EMBO Journal, 31(24), 4502–4510. https://doi.org/10.1038/emboj.2012.319CrossRefPubMedPubMedCentral

214.

Mueller, C., Berry, J. D., McKenna-Yasek, D. M., Gernoux, G., Owegi, M. A., Pothier, L. M., Douthwright, C. L., Gelevski, D., Luppino, S. D., Blackwood, M., Wightman, N. S., Oakley, D. H., Frosch, M. P., Flotte, T. R., Cudkowicz, M. E., & Brown, R. H., Jr. (2020). SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS. New England Journal of Medicine, 383(2), 151–158. https://doi.org/10.1056/NEJMoa2005056CrossRefPubMed

215.

Murdocca, M., Malgieri, A., Luchetti, A., Saieva, L., Dobrowolny, G., de Leonibus, E., Filareto, A., Quitadamo, M. C., Novelli, G., Musaro, A., & Sangiuolo, F. (2012). IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy. Molecular Medicine, 18, 1076–1085.PubMedPubMedCentralCrossRef

216.

Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., Rockenstein, E., Chao, M. V., Koo, E. H., Geschwind, D., Masliah, E., Chiba, A. A., & Tuszynski, M. H. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nature Medicine, 15(3), 331–337. https://doi.org/10.1038/nm.1912CrossRefPubMedPubMedCentral

217.

Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K., Karp, G. M., Qi, H., Woll, M. G., Chen, G., Zhang, N., Gabbeta, V., Vazirani, P., Bhattacharyya, A., Furia, B., Risher, N., Sheedy, J., Kong, R., … Metzger, F. (2014). Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science, 345(6197), 688–693.PubMedCrossRef

218.

Naumann, M., Pal, A., Goswami, A., Lojewski, X., Japtok, J., Vehlow, A., Naujock, M., Gunther, R., Jin, M., Stanslowsky, N., Reinhardt, P., Sterneckert, J., Frickenhaus, M., Pan-Montojo, F., Storkebaum, E., Poser, I., Freischmidt, A., Weishaupt, J. H., Holzmann, K., … Hermann, A. (2018). Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. Nature Communications, 9(1), 335. https://doi.org/10.1038/s41467-017-02299-1CrossRefPubMedPubMedCentral

219.

Nicole, S., Desforges, B., Millet, G., Lesbordes, J., Cifuentes-Diaz, C., Vertes, D., Cao, M. L., De Backer, F., Languille, L., Roblot, N., Joshi, V., Gillis, J. M., & Melki, J. (2003). Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle. Journal of Cell Biology, 161(3), 571–582.PubMedPubMedCentralCrossRef

220.

Nijssen, J., Aguila, J., & Hedlund, E. (2019). Axon-seq for in Depth Analysis of the RNA Content of Neuronal Processes. Bio Protocol, 9(14), 3312. https://doi.org/10.21769/BioProtoc.3312CrossRef

221.

Nishida, C. R., Gralla, E. B., & Valentine, J. S. (1994). Characterization of three yeast copper-zinc superoxide dismutase mutants analogous to those coded for in familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences USA, 91(21), 9906–9910. https://doi.org/10.1073/pnas.91.21.9906CrossRef

222.

Ojala, K. S., Reedich, E. J., DiDonato, C. J., & Meriney, S. D. (2021). In search of a cure: The development of therapeutics to alter the progression of spinal muscular atrophy. Brain Sciences, 11(2), 194. https://doi.org/10.3390/brainsci11020194CrossRefPubMedPubMedCentral

223.

O’Keefe L. FDA approves oral treatment for spinal muscular atrophy. FDA News Release, August 7, 2020. https://www.fda.gov/news-events/pressannouncements/fda-approves-oral-treatment-spinal-muscular-atrophy

224.

Oprea, G. E., Krober, S., McWhorter, M. L., Rossoll, W., Muller, S., Krawczak, M., Bassell, G. J., Beattie, C. E., & Wirth, B. (2008). Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science, 320(5875), 524–527.PubMedPubMedCentralCrossRef

225.

Orozco, D., Tahirovic, S., Rentzsch, K., Schwenk, B. M., Haass, C., & Edbauer, D. (2012). Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Reports, 13(8), 759–764. https://doi.org/10.1038/embor.2012.90CrossRefPubMedPubMedCentral

226.

Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Nature Communications, 6, 6244. https://doi.org/10.1038/ncomms7244CrossRefPubMed

227.

Palacino, J., Swalley, S. E., Song, C., Cheung, A. K., Shu, L., Zhang, X., Van, H. M., Shin, Y., Chin, D. N., Keller, C. G., Beibel, M., Renaud, N. A., Smith, T. M., Salcius, M., Shi, X., Hild, M., Servais, R., Jain, M., Deng, L., … Sivasankaran, R. (2015). SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nature Chemical Biology, 11(7), 511–517.PubMedCrossRef

228.

Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease [Review]. Nature Reviews. Neurology, 15(2), 73–88. https://doi.org/10.1038/s41582-018-0116-6CrossRefPubMed

229.

Pearn, J. (1978). Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. Journal of Medical Genetics, 15(6), 409–413.PubMedPubMedCentralCrossRef

230.

Pearn, J. (1980). Classification of spinal muscular atrophies. Lancet, 1(8174), 919–922.PubMedCrossRef

231.

Pearn, J. H. (1973). The gene frequency of acute Werdnig-Hoffmann disease (SMA type 1). A total population survey in North-East England. Journal of Medical Genetics, 10(3), 260–265.PubMedPubMedCentralCrossRef

232.

Pechmann, A., Langer, T., Schorling, D., Stein, S., Vogt, S., Schara, U., Kolbel, H., Schwartz, O., Hahn, A., Giese, K., Johannsen, J., Denecke, J., Weiss, C., Theophil, M., & Kirschner, J. (2018). Evaluation of children with SMA Type 1 under treatment with Nusinersen within the expanded access program in Germany. Journal of Neuromuscular Diseases, 5(2), 135–143. https://doi.org/10.3233/JND-180315CrossRefPubMedPubMedCentral

233.

Pellizzoni, L., Kataoka, N., Charroux, B., & Dreyfuss, G. (1998). A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 77(5), 727–736, 95(5), 615–624.

234.

Pennica, D., Arce, V., Swanson, T. A., Vejsada, R., Pollock, R. A., Armanini, M., Dudley, K., Phillips, H. S., Rosenthal, A., Kato, A. C., & Henderson, C. E. (1996). Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Neuron, 17(1), 63–74.PubMedCrossRef

235.

Pennica, D., Shaw, K. J., Swanson, T. A., Moore, M. W., Shelton, D. L., Zioncheck, K. A., Rosenthal, A., Taga, T., Paoni, N. F., & Wood, W. I. (1995). Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. Journal of Biological Chemistry, 270, 10915–10922.PubMedCrossRef

236.

Pirruccello-Straub, M., Jackson, J., Wawersik, S., Webster, M. T., Salta, L., Long, K., McConaughy, W., Capili, A., Boston, C., Carven, G. J., Mahanthappa, N. K., Turner, K. J., & Donovan, A. (2018). Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Science and Reports, 8(1), 2292. https://doi.org/10.1038/s41598-018-20524-9CrossRef

237.

Poirier, A., Weetall, M., Heinig, K., Bucheli, F., Schoenlein, K., Alsenz, J., Bassett, S., Ullah, M., Senn, C., Ratni, H., Naryshkin, N., Paushkin, S., & Mueller, L. (2018). Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs [Research Support, Non-U.S. Gov’t]. Pharmacology Research & Perspectives, 6(6), e00447. https://doi.org/10.1002/prp2.447CrossRef

238.

Pulst, S. M., Nechiporuk, A., Nechiporuk, T., Gispert, S., Chen, X. N., Lopes-Cendes, I., Pearlman, S., Starkman, S., Orozco-Diaz, G., Lunkes, A., DeJong, P., Rouleau, G. A., Auburger, G., Korenberg, J. R., Figueroa, C., & Sahba, S. (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature Genetics, 14(3), 269–276. https://doi.org/10.1038/ng1196-269CrossRefPubMed

239.

Ramdas, S., & Servais, L. (2020). New treatments in spinal muscular atrophy: An overview of currently available data [Review]. Expert Opinion on Pharmacotherapy, 21(3), 307–315. https://doi.org/10.1080/14656566.2019.1704732CrossRefPubMed

240.

Ramos, D. M., d’Ydewalle, C., Gabbeta, V., Dakka, A., Klein, S. K., Norris, D. A., Matson, J., Taylor, S. J., Zaworski, P. G., Prior, T. W., Snyder, P. J., Valdivia, D., Hatem, C. L., Waters, I., Gupte, N., Swoboda, K. J., Rigo, F., Bennett, C. F., Naryshkin, N., … Sumner, C. J. (2019). Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment [Clinical Trial Research Support, N.I.H., xtramural Research Support, Non-U.S. Gov’t]. Journal of Clinical Investigation, 129(11), 4817–4831. https://doi.org/10.1172/JCI124120CrossRefPubMedPubMedCentral

241.

Ramos, J. N., Hollinger, K., Bengtsson, N. E., Allen, J. M., Hauschka, S. D., & Chamberlain, J. S. (2019). Development of novel micro-dystrophins with enhanced functionality [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Molecular Therapy, 27(3), 623–635. https://doi.org/10.1016/j.ymthe.2019.01.002CrossRefPubMedPubMedCentral

242.

Ratni, H., Ebeling, M., Baird, J., Bendels, S., Bylund, J., Chen, K. S., Denk, N., Feng, Z., Green, L., Guerard, M., Jablonski, P., Jacobsen, B., Khwaja, O., Kletzl, H., Ko, C. P., Kustermann, S., Marquet, A., Metzger, F., Mueller, B., … Mueller, L. (2018). Discovery of Risdiplam, a selective Survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). Journal of Medicinal Chemistry, 61(15), 6501–6517. https://doi.org/10.1021/acs.jmedchem.8b00741CrossRefPubMed

243.

Ratni, H., Karp, G. M., Weetall, M., Naryshkin, N. A., Paushkin, S. V., Chen, K. S., McCarthy, K. D., Qi, H., Turpoff, A., Woll, M. G., Zhang, X., Zhang, N., Yang, T., Dakka, A., Vazirani, P., Zhao, X., Pinard, E., Green, L., David-Pierson, P., … Metzger, F. (2016). Specific correction of alternative survival motor Neuron 2 splicing by small molecules: Discovery of a potential novel medicine to treat spinal muscular atrophy [Research Support, Non-US Gov’t]. Journal of Medicinal Chemistry, 59(13), 6086–6100. https://doi.org/10.1021/acs.jmedchem.6b00459CrossRefPubMed

244.

Reaume, A. G., Elliott, J. L., Hoffman, E. K., Kowall, N. W., Ferrante, R. J., Siwek, D. F., Wilcox, H. M., Flood, D. G., Beal, M. F., Brown, R. H., Jr., Scott, R. W., & Snider, W. D. (1996). Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics, 13(1), 43–47.PubMedCrossRef

245.

Renton, A. E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y., Remes, A. M., Kaganovich, A., Scholz, S. W., Duckworth, J., Ding, J., Harmer, D. W., Hernandez, D. G., Johnson, J. O., Mok, K., Ryten, M., Trabzuni, D., Guerreiro, R. J., Orrell, R. W., Neal, J., Murray, A., Pearson, J., Jansen, I. E., Sondervan, D., Seelaar, H., Blake, D., Young, K., Halliwell, N., Callister, J. B., Toulson, G., Richardson, A., Gerhard, A., Snowden, J., Mann, D., Neary, D., Nalls, M. A., Peuralinna, T., Jansson, L., Isoviita, V. M., Kaivorinne, A. L., Holtta-Vuori, M., Ikonen, E., Sulkava, R., Benatar, M., Wuu, J., Chio, A., Restagno, G., Borghero, G., Sabatelli, M., Consortium, I., Heckerman, D., Rogaeva, E., Zinman, L., Rothstein, J. D., Sendtner, M., Drepper, C., Eichler, E. E., Alkan, C., Abdullaev, Z., Pack, S. D., Dutra, A., Pak, E., Hardy, J., Singleton, A., Williams, N. M., Heutink, P., Pickering-Brown, S., Morris, H. R., Tienari, P. J., & Traynor, B. J. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD [Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Neuron, 72(2), 257–268. https://doi.org/10.1016/j.neuron.2011.09.010

246.

Riessland, M., Kaczmarek, A., Schneider, S., Swoboda, K. J., Lohr, H., Bradler, C., Grysko, V., Dimitriadi, M., Hosseinibarkooie, S., Torres-Benito, L., Peters, M., Upadhyay, A., Biglari, N., Krober, S., Holker, I., Garbes, L., Gilissen, C., Hoischen, A., Nurnberg, G., … Wirth, B. (2017). Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. American Journal of Human Genetics, 100(2), 297–315. https://doi.org/10.1016/j.ajhg.2017.01.005CrossRefPubMedPubMedCentral

247.

Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012). Antisense-based therapy for the treatment of spinal muscular atrophy [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The Journal of Cell Biology, 199(1), 21–25. https://doi.org/10.1083/jcb.201207087CrossRefPubMedPubMedCentral

248.

Rindt, H., Buckley, D. M., Vale, S. M., Krogman, M., Rose, F. F., Jr., Garcia, M. L., & Lorson, C. L. (2012). Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscular Disorders, 22(3), 277–285. https://doi.org/10.1016/j.nmd.2011.10.012CrossRefPubMed

249.

Robbins, K. L., Glascock, J. J., Osman, E. Y., Miller, M. R., & Lorson, C. L. (2014). Defining the therapeutic window in a severe animal model of spinal muscular atrophy [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Human Molecular Genetics, 23(17), 4559–4568. https://doi.org/10.1093/hmg/ddu169CrossRefPubMedPubMedCentral

250.

Roberts, T. C., Langer, R., & Wood, M. J. A. (2020). Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 19(10), 673–694. https://doi.org/10.1038/s41573-020-0075-7CrossRefPubMedPubMedCentral

251.

Rochette, C. F., Gilbert, N., & Simard, L. R. (2001). SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens [Comparative Study Research Support, Non-U.S. Gov’t]. Human Genetics, 108(3), 255–266. https://doi.org/10.1007/s004390100473CrossRefPubMed

252.

Rogelj, B., Easton, L. E., Bogu, G. K., Stanton, L. W., Rot, G., Curk, T., Zupan, B., Sugimoto, Y., Modic, M., Haberman, N., Tollervey, J., Fujii, R., Takumi, T., Shaw, C. E., & Ule, J. (2012). Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain [Research Support, Non-U.S. Gov’t]. Scientific Reports, 2, 603. https://doi.org/10.1038/srep00603CrossRefPubMedPubMedCentral

253.

Rohrer, J. D., Isaacs, A. M., Mizielinska, S., Mead, S., Lashley, T., Wray, S., Sidle, K., Fratta, P., Orrell, R. W., Hardy, J., Holton, J., Revesz, T., Rossor, M. N., & Warren, J. D. (2015). C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis [Case Reports Research Support, Non-U.S. Gov’t Review]. The Lancet Neurology, 14(3), 291–301. https://doi.org/10.1016/S1474-4422(14)70233-9CrossRefPubMed

254.

Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H. X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S. M., Berger, R., Tanzi, R. E., Halperin, J. J., Herzfeldt, B., Van den Berg, R., Hung, W. Y., Bird, T., Deng, G., Mulder, D. W., Smyth, C., Laing, N. G., Soriano, E., Pericak-Vance, M. A., Haines, J., Rouleau, G. A., Gusella, J. S., Horvitz, H. R., & Brown Jr, R. H. (1993). Mutation in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 377(6547): 340–344, 362, 59–62.

255.

Rossoll, W., Jablonka, S., Andreassi, C., Kroning, A. K., Karle, K., Monani, U. R., & Sendtner, M. (2003). Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. Journal of Cell Biology, 163(4), 801–812.PubMedPubMedCentralCrossRef

256.

Rossoll, W., Kroning, A. K., Ohndorf, U. M., Steegborn, C., Jablonka, S., & Sendtner, M. (2002). Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: A role for Smn in RNA processing in motor axons? Human Molecular Genetics, 11(1), 93–105.PubMedCrossRef

257.

Rouget, R., Vigneault, F., Codio, C., Rochette, C., Paradis, I., Drouin, R., & Simard, L. R. (2005). Characterization of the survival motor neuron (SMN) promoter provides evidence for complex combinatorial regulation in undifferentiated and differentiated P19 cells [Research Support, Non-U.S. Gov’t]. Biochemical Journal, 385(Pt 2), 433–443. https://doi.org/10.1042/BJ20041024CrossRefPubMedCentralPubMed

258.

Rudnicki, S. A., Andrews, J. A., Duong, T., Cockroft, B. M., Malik, F. I., Meng, L., Wei, J., Wolff, A. A., Genge, A., Johnson, N. E., Tesi-Rocha, C., Connolly, A. M., Darras, B. T., Felice, K., Shieh, P. B., Mah, J. K., Statland, J., Campbell, C., Habib, A. A., … Day, J. W. (2021). Reldesemtiv in patients with spinal muscular atrophy: A phase 2 hypothesis-generating study. Neurotherapeutics. https://doi.org/10.1007/s13311-020-01004-3CrossRefPubMedPubMedCentral

259.

Rudnik-Schoneborn, S., Stolz, P., Varon, R., Grohmann, K., Schachtele, M., Ketelsen, U. P., Stavrou, D., Kurz, H., Hubner, C., & Zerres, K. (2004). Long-term observations of patients with infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Neuropediatrics, 35(3), 174–182.PubMedCrossRef

260.

Ruiz, R., Casanas, J. J., Torres-Benito, L., Cano, R., & Tabares, L. (2010). Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. Journal of Neuroscience, 30(3), 849–857.PubMedCrossRef

261.

Saal, L., Briese, M., Kneitz, S., Glinka, M., & Sendtner, M. (2014). Subcellular transcriptome alterations in a cell culture model of spinal muscular atrophy point to widespread defects in axonal growth and presynaptic differentiation. RNA, 20(11), 1789–1802.PubMedPubMedCentralCrossRef

262.

Sanpei, K., Takano, H., Igarashi, S., Sato, T., Oyake, M., Sasaki, H., Wakisaka, A., Tashiro, K., Ishida, Y., Ikeuchi, T., Koide, R., Saito, M., Sato, A., Tanaka, T., Hanyu, S., Takiyama, Y., Nishizawa, M., Shimizu, N., Nomura, Y., … Tsuji, S. (1996). Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nature Genetics, 14(3), 277–284. https://doi.org/10.1038/ng1196-277CrossRefPubMed

263.

Scharf, J. M., Damron, D., Frisella, A., Bruno, S., Beggs, A. H., Kunkel, L. M., & Dietrich, W. F. (1996). The mouse region syntenic for human spinal muscular atrophy lies within the Lgn1 critical interval and contains multiple copies of Naip exon 5. Genomics, 38(3), 405–417.PubMedCrossRef

264.

Schrank, B., Gotz, R., Gunnersen, J. M., Ure, J. M., Toyka, K. V., Smith, A. G., & Sendtner, M. (1997). Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proceedings of the National academy of Sciences of the United States of America, 94(18), 9920–9925.PubMedPubMedCentralCrossRef

265.

Sendtner, M., Arakawa, Y., St”ckli, K. A., Kreutzberg, G. W., & Thoenen, H. (1991). Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival. Journal of Cell Science Supplement, 15, 103–109.PubMedCrossRef

266.

Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y. A. (1992). Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature 377(6547), 340–344, 360, 757–758

267.

Sendtner, M., Kreutzberg, G. W., & Thoenen, H. (1990). Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature 377(6547), 340–4, 345, 440–441.

268.

Sendtner, M., Schmalbruch, H., Stockli, K. A., Carroll, P., Kreutzberg, G. W., & Thoenen, H. (1992). Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 377(6547): 340–344, 358(6386), 502–504.

269.

Sendtner, M., & Thoenen, H. (1994). Neurodegenerative disease: Oxidative stress and motorneuron disease. Current Biology, 4, 1036–1039.PubMedCrossRef

270.

Sergott, R. C., Amorelli, G. M., Baranello, G., Barreau, E., Beres, S., Kane, S., Mercuri, E., Orazi, L., SantaMaria, M., Tremolada, G., Santarsiero, D., Waskowska, A., Yashiro, S., Denk, N., Furst-Recktenwald, S., Gerber, M., Gorni, K., Jaber, B., Jacobsen, B., … Firefish, S. J. W. G. (2021). Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy [Research Support, Non-U.S. Gov’t]. Annals of Clinical and Translational Neurology, 8(1), 54–65. https://doi.org/10.1002/acn3.51239CrossRefPubMed

271.

Shafey, D., Cote, P. D., & Kothary, R. (2005). Hypomorphic Smn knockdown C2C12 myoblasts reveal intrinsic defects in myoblast fusion and myotube morphology. Experimental Cell Research, 311(1), 49–61. https://doi.org/10.1016/j.yexcr.2005.08.019CrossRefPubMed

272.

Simic, G., Seso-Simic, D., Lucassen, P. J., Islam, A., Krsnik, Z., Cviko, A., Jelasic, D., Barisic, N., Winblad, B., Kostovic, I., & Kruslin, B. (2000). Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann disease [Research Support, Non-U.S. Gov’t]. Journal of Neuropathology and Experimental Neurology, 59(5), 398–407. https://doi.org/10.1093/jnen/59.5.398CrossRefPubMed

273.

Simon, C. M., Blanco-Redondo, B., Buettner, J. M., Pagiazitis, J. G., Fletcher, E. V., Sime Longang, J. K., & Mentis, G. Z. (2021). Chronic pharmacological increase of neuronal activity improves sensory-motor dysfunction in spinal muscular atrophy mice. Journal of Neuroscience, 41(2), 376–389. https://doi.org/10.1523/JNEUROSCI.2142-20.2020CrossRefPubMed

274.

Simon, C. M., Jablonka, S., Ruiz, R., Tabares, L., & Sendtner, M. (2010). Ciliary neurotrophic factor-induced sprouting preserves motor function in a mouse model of mild spinal muscular atrophy [Research Support, Non-U.S. Gov’t]. Human Molecular Genetics, 19(6), 973–986. https://doi.org/10.1093/hmg/ddp562CrossRefPubMed

275.

Simon, C. M., Van Alstyne, M., Lotti, F., Bianchetti, E., Tisdale, S., Watterson, D. M., Mentis, G. Z., & Pellizzoni, L. (2019). Stasimon Contributes to the Loss of Sensory Synapses and Motor Neuron Death in a Mouse Model of Spinal Muscular Atrophy. Cell Report, 29(12), 3885-3901e3885. https://doi.org/10.1016/j.celrep.2019.11.058CrossRef

276.

Singh, R. N., Ottesen, E. W., & Singh, N. N. (2020). The first orally deliverable small molecule for the treatment of spinal muscular atrophy [review]. Neuroscience Insights, 15, 2633105520973985. https://doi.org/10.1177/2633105520973985CrossRefPubMedPubMedCentral

277.

Singh, R. N., & Singh, N. N. (2018). Mechanism of splicing regulation of spinal muscular atrophy genes. Advances in Neurobiology, 20, 31–61. https://doi.org/10.1007/978-3-319-89689-2_2CrossRefPubMedPubMedCentral

278.

Sivadasan, R., Hornburg, D., Drepper, C., Frank, N., Jablonka, S., Hansel, A., Lojewski, X., Sterneckert, J., Hermann, A., Shaw, P. J., Ince, P. G., Mann, M., Meissner, F., & Sendtner, M. (2016). C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nature Neuroscience, 19(12), 1610–1618. https://doi.org/10.1038/nn.4407CrossRefPubMed

279.

Son, H. W., & Yokota, T. (2018). Recent advances and clinical applications of exon inclusion for spinal muscular atrophy [Research Support, Non-U.S. Gov’t Review]. Methods in Molecular Biology, 1828, 57–68. https://doi.org/10.1007/978-1-4939-8651-4_3CrossRefPubMed

280.

Song, Y., Morales, L., Malik, A. S., Mead, A. F., Greer, C. D., Mitchell, M. A., Petrov, M. T., Su, L. T., Choi, M. E., Rosenblum, S. T., Lu, X., VanBelzen, D. J., Krishnankutty, R. K., Balzer, F. J., Loro, E., French, R., Propert, K. J., Zhou, S., Kozyak, B. W., … Stedman, H. H. (2019). Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models [Research Support, NIH, Extramural Research Support, Non-U.S. Gov’t]. Nature Medicine, 25(10), 1505–1511. https://doi.org/10.1038/s41591-019-0594-0CrossRefPubMedPubMedCentral

281.

Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Reid, S. W., Blair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., Nikolics, K., & Parada, L. F. (1991). The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trk B tyrosine kinase receptor. Cell 77(5): 727–736, 65, 895–903.

282.

Stratigopoulos, G., Lanzano, P., Deng, L., Guo, J., Kaufmann, P., Darras, B., Finkel, R., Tawil, R., McDermott, M. P., Martens, W., Devivo, D. C., & Chung, W. K. (2010). Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Archives of Neurology, 67(10), 1252–1256. https://doi.org/10.1001/archneurol.2010.239CrossRefPubMed

283.

Strauss, K. A., Carson, V. J., Brigatti, K. W., Young, M., Robinson, D. L., Hendrickson, C., Fox, M. D., Reed, R. M., Puffenberger, E. G., Mackenzie, W., & Miller, F. (2018). Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy. Journal of Pediatric Orthopedics, 38(10), e610–e617. https://doi.org/10.1097/BPO.0000000000001247CrossRefPubMedPubMedCentral

284.

Sumner, C. J., Wee, C. D., Warsing, L. C., Choe, D. W., Ng, A. S., Lutz, C., & Wagner, K. R. (2009). Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Human Molecular Genetics, 18(17), 3145–3152. https://doi.org/10.1093/hmg/ddp253CrossRefPubMedPubMedCentral

285.

Sunyach, C., Michaud, M., Arnoux, T., Bernard-Marissal, N., Aebischer, J., Latyszenok, V., Gouarne, C., Raoul, C., Pruss, R. M., Bordet, T., & Pettmann, B. (2012). Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model [Comparative Study Research Support, Non-U.S. Gov’t]. Neuropharmacology, 62(7), 2346–2352. https://doi.org/10.1016/j.neuropharm.2012.02.013CrossRefPubMed

286.

Swinnen, B., Bento-Abreu, A., Gendron, T. F., Boeynaems, S., Bogaert, E., Nuyts, R., Timmers, M., Scheveneels, W., Hersmus, N., Wang, J., Mizielinska, S., Isaacs, A. M., Petrucelli, L., Lemmens, R., Van Damme, P., Van Den Bosch, L., & Robberecht, W. (2018). A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism [Research Support, Non-U.S. Gov’t]. Acta Neuropathologica, 135(3), 427–443. https://doi.org/10.1007/s00401-017-1796-5CrossRefPubMed

287.

Takanashi, J. I., & Takase, N. (2019). Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [Comment]. Neurology, 93(10), 464. https://doi.org/10.1212/WNL.0000000000008074CrossRefPubMed

288.

Tan, A. Y., & Manley, J. L. (2010). TLS inhibits RNA polymerase III transcription [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Molecular and Cellular Biology, 30(1), 186–196. https://doi.org/10.1128/MCB.00884-09CrossRefPubMed

289.

Tarr, T. B., Malick, W., Liang, M., Valdomir, G., Frasso, M., Lacomis, D., Reddel, S. W., Garcia-Ocano, A., Wipf, P., & Meriney, S. D. (2013). Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. Journal of Neuroscience, 33(25), 10559–10567.PubMedCrossRef

290.

Taylor, J. P., Brown, R. H., Jr., & Cleveland, D. W. (2016). Decoding ALS: from genes to mechanism [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. Nature, 539(7628), 197–206. https://doi.org/10.1038/nature20413CrossRefPubMedPubMedCentral

291.

Tejero, R., Balk, S., Franco-Espin, J., Ojeda, J., Hennlein, L., Drexl, H., Dombert, B., Clausen, J. D., Torres-Benito, L., Saal-Bauernschubert, L., Blum, R., Briese, M., Appenzeller, S., Tabares, L., & Jablonka, S. (2020). R-Roscovitine improves motoneuron function in mouse models for spinal muscular atrophy. iScience, 23(2), 100826. https://doi.org/10.1016/j.isci.2020.100826CrossRefPubMedPubMedCentral

292.

Tejero, R., Lopez-Manzaneda, M., Arumugam, S., & Tabares, L. (2016). Synaptotagmin-2, and -1, linked to neurotransmission impairment and vulnerability in Spinal Muscular Atrophy. Human Molecular Genetics, 25(21), 4703–4716.PubMed

293.

Torres-Benito, L., Schneider, S., Rombo, R., Ling, K. K., Grysko, V., Upadhyay, A., Kononenko, N. L., Rigo, F., Bennett, C. F., & Wirth, B. (2019). NCALD antisense oligonucleotide therapy in addition to nusinersen further ameliorates spinal muscular atrophy in mice. American Journal of Human Genetics, 105(1), 221–230. https://doi.org/10.1016/j.ajhg.2019.05.008CrossRefPubMedPubMedCentral

294.

Tsai, L. K., Chen, C. L., Ting, C. H., Lin-Chao, S., Hwu, W. L., Dodge, J. C., Passini, M. A., & Cheng, S. H. (2014). Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Molecular Therapy, 22(8), 1450–1459. https://doi.org/10.1038/mt.2014.84CrossRefPubMedPubMedCentral

295.

Tseng, Y. T., Chen, C. S., Jong, Y. J., Chang, F. R., & Lo, Y. C. (2016). Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy. Pharmacological Research, 111, 58–75. https://doi.org/10.1016/j.phrs.2016.05.023CrossRefPubMed

296.

Tsuiji, H., Iguchi, Y., Furuya, A., Kataoka, A., Hatsuta, H., Atsuta, N., Tanaka, F., Hashizume, Y., Akatsu, H., Murayama, S., Sobue, G., & Yamanaka, K. (2013). Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Molecular Medicine, 5(2), 221–234.PubMedPubMedCentralCrossRef

297.

Udagawa, T., Fujioka, Y., Tanaka, M., Honda, D., Yokoi, S., Riku, Y., Ibi, D., Nagai, T., Yamada, K., Watanabe, H., Katsuno, M., Inada, T., Ohno, K., Sokabe, M., Okado, H., Ishigaki, S., & Sobue, G. (2015). FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization [Research Support, Non-U.S. Gov’t]. Nature Communications, 6, 7098. https://doi.org/10.1038/ncomms8098CrossRefPubMed

298.

Upadhyay, A., Hosseinibarkooie, S., Schneider, S., Kaczmarek, A., Torres-Benito, L., Mendoza-Ferreira, N., Overhoff, M., Rombo, R., Grysko, V., Kye, M. J., Kononenko, N. L., & Wirth, B. (2019). Neurocalcin delta knockout impairs adult neurogenesis whereas half reduction is not pathological. Frontiers in Molecular Neuroscience, 12, 19. https://doi.org/10.3389/fnmol.2019.00019CrossRefPubMedPubMedCentral

299.

Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010). Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Science Translational Medicine, 2(35), 35ra42. https://doi.org/10.1126/scitranslmed.3000830CrossRefPubMed

300.

Van Alstyne, M., Simon, C. M., Sardi, S. P., Shihabuddin, L. S., Mentis, G. Z., & Pellizzoni, L. (2018). Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.]. Genes & Development, 32(15–16), 1045–1059. https://doi.org/10.1101/gad.316059.118CrossRef

301.

Van Alstyne, M., Tattoli, I., Delestree, N., Recinos, Y., Workman, E., Shihabuddin, L. S., Zhang, C., Mentis, G. Z., & Pellizzoni, L. (2021). Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nature Neuroscience. https://doi.org/10.1038/s41593-021-00827-3CrossRefPubMedPubMedCentral

302.

van Blitterswijk, M., DeJesus-Hernandez, M., Niemantsverdriet, E., Murray, M. E., Heckman, M. G., Diehl, N. N., Brown, P. H., Baker, M. C., Finch, N. A., Bauer, P. O., Serrano, G., Beach, T. G., Josephs, K. A., Knopman, D. S., Petersen, R. C., Boeve, B. F., Graff-Radford, N. R., Boylan, K. B., Petrucelli, L., … Rademakers, R. (2013). Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. The Lancet Neurology, 12(10), 978–988. https://doi.org/10.1016/S1474-4422(13)70210-2CrossRefPubMed

303.

Van Langenhove, T., van der Zee, J., Sleegers, K., Engelborghs, S., Vandenberghe, R., Gijselinck, I., Van den Broeck, M., Mattheijssens, M., Peeters, K., De Deyn, P. P., Cruts, M., & Van Broeckhoven, C. (2010). Genetic contribution of FUS to frontotemporal lobar degeneration [Research Support, Non-U.S. Gov’t]. Neurology, 74(5), 366–371. https://doi.org/10.1212/WNL.0b013e3181ccc732CrossRefPubMed

304.

Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K. L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., Leigh, P. N., Blair, I. P., Nicholson, G., de Belleroche, J., … Shaw, C. E. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 [Research Support, Non-U.S. Gov’t]. Science, 323(5918), 1208–1211. https://doi.org/10.1126/science.1165942CrossRefPubMedPubMedCentral

305.

Verhaart, I. E. C., Robertson, A., Wilson, I. J., Aartsma-Rus, A., Cameron, S., Jones, C. C., Cook, S. F., & Lochmuller, H. (2017). Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy—A literature review. Orphanet Journal of Rare Diseases, 12(1), 124. https://doi.org/10.1186/s13023-017-0671-8CrossRefPubMedPubMedCentral

306.

Verhaart, I. E. C., & Aartsma-Rus, A. (2019). Therapeutic developments for Duchenne muscular dystrophy. Nature Reviews Neurology, 15(7), 373–386. https://doi.org/10.1038/s41582-019-0203-3CrossRefPubMed

307.

Villalon, E., Shababi, M., Kline, R., Lorson, Z. C., Florea, K. M., & Lorson, C. L. (2018). Selective vulnerability in neuronal populations in nmd/SMARD1 mice. Human Molecular Genetics, 27(4), 679–690. https://doi.org/10.1093/hmg/ddx434CrossRefPubMed

308.

Vrbova, G., & Slawinska, U. (2018). Critical period of neuromuscular development: Importance for a new treatment of SMA. Neuromuscular Disorders, 28(5), 385–393. https://doi.org/10.1016/j.nmd.2018.03.007CrossRefPubMed

309.

Wadman, R. I., Stam, M., Jansen, M. D., van der Weegen, Y., Wijngaarde, C. A., Harschnitz, O., Sodaar, P., Braun, K. P., Dooijes, D., Lemmink, H. H., van den Berg, L. H., & van der Pol, W. L. (2016). A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls [Clinical Trial Comparative Study]. PLoS ONE, 11(11), e0167087. https://doi.org/10.1371/journal.pone.0167087CrossRefPubMedPubMedCentral

310.

Wadman, R. I., Vrancken, A. F., van den Berg, L. H., & van der Pol, W. L. (2012). Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology, 79(20), 2050–2055. https://doi.org/10.1212/WNL.0b013e3182749ecaCrossRefPubMed

311.

Walker, M. P., Rajendra, T. K., Saieva, L., Fuentes, J. L., Pellizzoni, L., & Matera, A. G. (2008). SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain. Human Molecular Genetics, 17(21), 3399–3410. https://doi.org/10.1093/hmg/ddn234CrossRefPubMedPubMedCentral

312.

Wang, D., Tai, P. W. L., & Gao, G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery, 18(5), 358–378. https://doi.org/10.1038/s41573-019-0012-9CrossRefPubMedPubMedCentral

313.

Wang, X., Arai, S., Song, X., Reichart, D., Du, K., Pascual, G., Tempst, P., Rosenfeld, M. G., Glass, C. K., & Kurokawa, R. (2008). Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription [Research Support, N.I.H., Extramural]. Nature, 454(7200), 126–130. https://doi.org/10.1038/nature06992CrossRefPubMedPubMedCentral

314.

Weaver, J. J., Natarajan, N., Shaw, D. W. W., Apkon, S. D., Koo, K. S. H., Shivaram, G. M., & Monroe, E. J. (2018). Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: Early results of technical success and safety. Pediatric Radiology, 48(3), 392–397. https://doi.org/10.1007/s00247-017-4031-6CrossRefPubMed

315.

Wen, X., Tan, W., Westergard, T., Krishnamurthy, K., Markandaiah, S. S., Shi, Y., Lin, S., Shneider, N. A., Monaghan, J., Pandey, U. B., Pasinelli, P., Ichida, J. K., & Trotti, D. (2014). Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Neuron, 84(6), 1213–1225. https://doi.org/10.1016/j.neuron.2014.12.010CrossRefPubMedPubMedCentral

316.

Werdnig, G. (1891). Zwei frühinfantile hereditäre Fälle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Archiv für Psychiatrie und Nervenkrankheiten, 22, 437.CrossRef

317.

Winkler, C., Eggert, C., Gradl, D., Meister, G., Giegerich, M., Wedlich, D., Laggerbauer, B., & Fischer, U. (2005). Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes & Development, 19(19), 2320–2330.CrossRef

318.

Wirth, B. (2000). An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Human Mutation, 15(3), 228–237.PubMedCrossRef

319.

Wirth, B., Brichta, L., Schrank, B., Lochmuller, H., Blick, S., Baasner, A., & Heller, R. (2006). Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Human Genetics, 119(4), 422–428. (IN FILE).PubMedCrossRef

320.

Wirth, B., Herz, M., Wetter, A., Moskau, S., Hahnen, E., Rudnik-Schoneborn, S., Wienker, T., & Zerres, K. (1999). Quantitative analysis of survival motor neuron copies: Identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. American Journal of Human Genetics, 64(5), 1340–1356.PubMedPubMedCentralCrossRef

321.

Wirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020). Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next. Annual Review of Genomics and Human Genetics. https://doi.org/10.1146/annurev-genom-102319-103602CrossRefPubMed

322.

Wong, V., Arriga, R., Ip, N., & Lindsay, R. M. (1993). The neurotrophins BDNF, NT-3 and NT-4/5, but not NGF, upregulate the cholinergic phenotype of developing motoneurons. European Journal of Neuroscience, 5, 466–474. (IN FILE).PubMedCrossRef

323.

Yamazaki, T., Chen, S., Yu, Y., Yan, B., Haertlein, T. C., Carrasco, M. A., Tapia, J. C., Zhai, B., Das, R., Lalancette-Hebert, M., Sharma, A., Chandran, S., Sullivan, G., Nishimura, A. L., Shaw, C. E., Gygi, S. P., Shneider, N. A., Maniatis, T., & Reed, R. (2012). FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Reports, 2(4), 799–806.PubMedCrossRef

324.

Yan, Z., Chi, P., Bibb, J. A., Ryan, T. A., & Greengard, P. (2002). Roscovitine: A novel regulator of P/Q-type calcium channels and transmitter release in central neurons. Journal of Physiology, 540(Pt 3), 761–770.PubMedPubMedCentralCrossRef

325.

Yasuda, K., Clatterbuck-Soper, S. F., Jackrel, M. E., Shorter, J., & Mili, S. (2017). FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. Journal of Cell Biology, 216(4), 1015–1034. https://doi.org/10.1083/jcb.201608022CrossRefPubMedPubMedCentral

326.

Yasuda, K., & Mili, S. (2016). Dysregulated axonal RNA translation in amyotrophic lateral sclerosis. Wiley Interdisciplinary Reviews: RNA, 7(5), 589–603. https://doi.org/10.1002/wrna.1352CrossRefPubMed

327.

Yokoi, S., Udagawa, T., Fujioka, Y., Honda, D., Okado, H., Watanabe, H., Katsuno, M., Ishigaki, S., & Sobue, G. (2017). 3’UTR length-dependent control of SynGAP Isoform alpha2 mRNA by FUS and ELAV-like proteins promotes dendritic spine maturation and cognitive function. Cell Reports, 20(13), 3071–3084. https://doi.org/10.1016/j.celrep.2017.08.100CrossRefPubMed

328.

Yoon, J. H., Chandrasekharan, K., Xu, R., Glass, M., Singhal, N., & Martin, P. T. (2009). The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin [Research Support, N.I.H., Extramural]. Molecular and Cellular Neuroscience, 41(4), 448–463. https://doi.org/10.1016/j.mcn.2009.04.013CrossRefPubMed

329.

Yoshiyama, Y., Lee, V. M., & Trojanowski, J. Q. (2013). Therapeutic strategies for tau mediated neurodegeneration [Research Support, Non-U.S. Gov’t Review]. Journal of Neurology, Neurosurgery & Psychiatry, 84(7), 784–795. https://doi.org/10.1136/jnnp-2012-303144CrossRef

330.

Zaworski, P., von Herrmann, K. M., Taylor, S., Sunshine, S. S., McCarthy, K., Risher, N., Newcomb, T., Weetall, M., Prior, T. W., Swoboda, K. J., Chen, K. S., & Paushkin, S. (2016). SMN protein can be reliably measured in whole blood with an Electrochemiluminescence (ECL) immunoassay: Implications for clinical trials [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. PLoS ONE, 11(3), 640. https://doi.org/10.1371/journal.pone.0150640CrossRef

331.

Zhou, H., Meng, J., Malerba, A., Catapano, F., Sintusek, P., Jarmin, S., Feng, L., Lu-Nguyen, N., Sun, L., Mariot, V., Dumonceaux, J., Morgan, J. E., Gissen, P., Dickson, G., & Muntoni, F. (2020). Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. Journal of Cachexia, Sarcopenia and Muscle, 11(3), 768–782. https://doi.org/10.1002/jcsm.12542CrossRefPubMedPubMedCentral

332.

Zhu, X., Hadhazy, M., Wehling, M., Tidball, J. G., & McNally, E. M. (2000). Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Letters, 474(1), 71–75. https://doi.org/10.1016/s0014-5793(00)01570-2CrossRefPubMed

333.

Zinszner, H., Sok, J., Immanuel, D., Yin, Y., & Ron, D. (1997). TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. Journal of Cell Science, 110(Pt 15), 1741–1750.PubMedCrossRef

334.

Zou, Z. Y., Zhou, Z. R., Che, C. H., Liu, C. Y., He, R. L., & Huang, H. P. (2017). Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis [Meta-Analysis Review Systematic Review]. Journal of Neurology, Neurosurgery and Psychiatry, 88(7), 540–549. https://doi.org/10.1136/jnnp-2016-315018CrossRefPubMed

335.

Zu, T., Liu, Y., Banez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T. M., Harms, M. B., Falchook, A. E., Subramony, S. H., Ostrow, L. W., Rothstein, J. D., Troncoso, J. C., & Ranum, L. P. (2013). RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia [Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Proceedings of the National Academy of Sciences USA, 110(51), E4968-4977. https://doi.org/10.1073/pnas.1315438110CrossRef

At a glance: The STEP trials

Springer Medicine

Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders

Abstract

Background

Main body

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Does diabetes mellitus affect the safety profile of valproic acid for the treatment of status epilepticus? A retrospective cohort study

No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache

Historical review: the German Neurological Society and its honorary members (1952–1982)

Side matters: differences in functional outcome and quality of life after thrombectomy in left and right hemispheric stroke

Long-term efficacy with deep brain stimulation of the globus pallidus internus in cervical dystonia: a retrospective monocentric study

Prognostic markers of post-stroke depression (PROMoSD): study protocol of a prospective single-center observational study on raphe hypoechogenicity as a predictor of post-stroke depression